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Abstract 
Multidrug-resistant tuberculosis (MDR-TB) is a public health problem in several 
countries such as Angola, India, China, Kenya, and Nigeria. Due to the increasing high 
burden of MDR-TB, most of these countries do not have adequate capacities to manage 
MDR-TB patients effectively. This study investigated the effect of model of care; human 
immunodeficiency virus comorbidity; and demographic factors such as age, gender, and 
marital status on the treatment outcomes of MDR-TB patients in Nigeria. The study was 
based on the analysis of secondary data of 402 MDR-TB patients accessed from the data 
systems of the National Tuberculosis, Buruli Ulcer, and Leprosy Control Program. The 
theoretical framework for this study was the health belief model. The results of the study 
showed that treatment outcomes were similar for hospital and community-based models 
of care. Age was the only factor found to be significantly associated with treatment 
outcomes; age > than 40 years was a predictor of unsuccessful treatment outcomes 
among MDR-TB patients at a p-value of 0.026. In the multivariate logistics regression 
analysis, age and model of care were found to be significantly associated with treatment 
outcomes at p-values of 0.043 and 0.048, respectively. Marital status, gender, and HIV 
comorbidity were not significantly associated with treatment outcomes. Implications of 
the findings of this study for social change in a health care program include opportunities 
to help reduce the number of patients on waiting lists for MDR-TB treatment. These 
strategies may ultimately help to reduce the spread of MDR-TB infection as well as the 
mortality associated with late treatment. 
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Section 1: Foundation of the Study and Literature Review  
 Introduction  
In this study, I investigated the effect of the model of care and existence of co-
morbidities on the treatment outcomes among multidrug-resistant tuberculosis (MDR-
TB) patients.  MDR-TB has become increasingly prevalent in countries such as China, 
India, and Nigeria among others (World Health Organization [WHO], 2016). In 2013, 
136,000 multidrug/rifampicin resistant tuberculosis (MDR/RR-TB) cases were reported 
globally; this increased to 153,119 in 2016 and 160,684 cases in 2017 (WHO, 2014, 
2018b). In 2016, an additional 110,000 cases rifampicin resistant tuberculosis (RR-TB) 
cases that were also susceptible to isoniazid were notified globally (WHO, 2017).  
The burden of tuberculosis (TB) globally is currently estimated to be 558,000 
(WHO, 2018b). Similarly, an estimated 230,000 deaths from MDR/RR-TB were reported 
in 2017 (WHO, 2018b). Nigeria has remained one of the high burden countries for MDR-
TB with an ever increasing trend of the disease from 550 cases detected in 2013 to 798 in 
2014; 1,242 in 2015 and 2,286 in 2017 (USAID, 2016; WHO, 2016, 2018a). MDR-TB is 
defined as Mycobacterium tuberculosis strains that are resistant to both isoniazid and 
rifampicin (Falzon et al., 2011). The increasing trend in the burden of MDR-TB has made 
it pertinent to increase the capacities of individual high burden countries to manage 
patients affected by the disease. Against this backdrop, efforts to rapidly scale up the 
capacities of MDR-TB treatment services are underway in high burden countries such as 
Nigeria.  
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In Nigeria, the national guidelines for the management of MDR-TB are in line 
with WHO guidelines, which recommend ambulatory care to include 8 months of 
intensive phase in specialized treatment centers and 12 months of continuation in the 
community (Falzon et al., 2011). The intensive phase comprises daily injections of 
aminoglycosides as well as oral medications that are toxic and less effective than the 
medications used to manage drug susceptible TB ( Tanzania Ministry of Health and 
Social Welfare National Tuberculosis and Leprosy Programme [NTLP], 2013). The 
continuation phase includes the use of mainly oral medications for 12 months.  
Based on review of programmatic reports, Nigeria adopted the complete 
community care model in 2013; this model of care comprises community or home-based 
management of MDR-TB from enrollment to end of treatment regimen. More recently, 
the shorter regimen as stipulated by the latest WHO guidelines were piloted in the 
country and became a mandatory component of the treatment guidelines in 2018. The 
shorter regimen includes a 4–6 months intensive phase with a combination of kanamycin, 
moxifloxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid, and 
ethambutol, followed by a 5-month continuation phase containing moxifloxacin, 
clofazimine, ethambutol, and pyrazinamide (Chee et al., 2017). 
Currently, countries employ varied models of care, which include hospital-based, 
ambulatory and complete community-based models of care. The need for scale-up of 
MDR-TB services raises questions as to the sustainability of the hospital-based model of 
care which is often inadequate, in resource-limited settings, to meet the demand for 
treatment services (Salje et al., 2014). The number of bed spaces and staffing required to 
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enroll and manage MDR-TB patients in such settings often exceed the available resources 
(Taneja, 2017). In question is also the cost effectiveness of the hospital-based model of 
care relative to ambulatory and community-based treatment models. These issues are 
currently relevant to the Nigerian MDR-TB program because of the increasing burden of 
the disease in the country and the need to ensure a patient-centered approach to the 
management of MDR-TB patients. Additionally, the ultimate goal of the National TB 
program is to provide the best quality of TB care in the most effective and efficient 
manner. Against this background, it is essential that the effect of model of care and other 
relevant factors such as the existence of co-morbidities, among others, on the treatment 
outcomes of MDR-TB patients is investigated. 
Potential Positive Social Change Implications 
A major pillar in the international standard for TB care is the emphasis on a 
patient-centered approach in the management of TB (Mohan, 2007). In line with this, it is 
critical that policies that impact treatment conditions, quality of care, and outcomes of 
MDR-TB patients are implemented and evaluated with the aim of ensuring an optimal 
quality of care that will result in the best outcomes possible for the patients that are being 
managed. The implications for social change for this study therefore include the 
possibility of improving the quality of treatment provided to MDR-TB patients by 
ensuring the scale-up of the optimal and most effective model of care based on empirical 
evidence. This study includes information about the effect of co-morbidities such as HIV 
and demographic factors such as age, gender and marital status on treatment outcomes 
among MDR-TB patients. A deeper understanding of the relationship between these 
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factors may inform the development of policies and guidelines that can address existing 
gaps in the quality of care provided to MDR-TB patients. Other implications for social 
change include more gender-sensitive treatment guidelines, adaptation of specific 
treatment model for different age categories and special provisions for the management 
of co-morbidities in MDR-TB control programs. 
Problem Statement 
The burden of TB continues to be a public health issue in several countries 
including Nigeria (WHO, 2017). According to the 2017 Global TB Report, about 10.4 
million people were diagnosed of TB out of which 1.7 million people died of the disease 
(WHO, 2017). The situation is further worsened in countries such as Angola, India, 
China, Kenya, and Nigeria, among others, where there has been a rise in the incidence of 
drug resistant strain of the disease (WHO, 2017). MDR-TB remains a major threat to the 
progress made in the control of the global TB epidemics. The treatment for MDR-TB is 
expensive, less effective, and more toxic than that of drug susceptible TB (Patel et al., 
2016). Hence, there is need for specific actions toward addressing the risk factors 
associated with the disease while ensuring adequate treatment capacities and quality of 
care are made available.  
In most settings, the treatment of MDR-TB has been provided through centralized 
and prolonged in-patient care. Several limitations have been associated with this model of 
care, among which are low retention, high risk of nosocomial infections, high cost of 
treatment, and high risk of transmission of MDR-TB (Ho, Byrne, Linh, Jaramillo, & Fox, 
2017). This gave rise to the ambulatory care model which includes a short stay in the 
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hospital for about 6–8 months followed by community-based management of the disease 
(Falzon et al., 2011). WHO recommended the ambulatory care model as the mainstay for 
MDR-TB treatment (Bassili et al., 2013). This recommendation however requires 
empirical evidence to support the rapid scale-up of the community-based model of MDR-
TB care in settings with huge gaps in MDR-TB case detection and enrollment due to 
inadequate bed spaces such as Nigeria (Molla et al., 2017; USAID, 2016). Beyond that, it 
is critical that patients are offered the most effective model of care in terms of patients’ 
treatment and survival outcomes. Similarly, post-implementation evidence is needed in 
resource-limited settings with regards to the effectiveness of community-based MDR-TB 
care model. 
Since the introduction of the Xpert machine in Nigeria in 2010, there has been a 
steady rise in the detection of MDR-TB due to the sensitivity of the diagnostic 
technology (Abdurrahman et al., 2014). Notification of MDR-TB increased from 21 in 
2010 to 550 in 2013 and 798 in 2014 (WHO, 2011, 2014, 2015a). The Xpert MTB/RIF is 
a rapid diagnostic test which detects presence of TB bacilli as well as rifampicin 
resistance (Kuyinu, Odugbemi, Salisu-Olatunji, & Adepoju, 2018; Mustapha et al., 
2015). The detection of rifampicin resistance is usually an indication of MDR-TB 
because patients that are resistant to Rifampicin are often also resistant to Isoniazid 
(Kumar, Datta, & Kumar, 2016). Although, there is limited access to the machine due to 
weak infrastructure at the primary health care facilities, MDR-TB case detection has 
increased in areas where the machines are situated (Mustapha et al., 2015). This rapid 
increase in case detection has called for a scale up of the treatment facilities for MDR-TB 
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cases detected to enable adequate enrollment of patients for treatment. However, a gap in 
case detection and those that are subsequently enrolled for treatment has remained an 
issue in the country (USAID, 2016). In response to this gap, the ambulatory care model 
has been adopted in Nigeria, along with a complete community-based or out-patient care 
model, which means that patients are started and completed on treatment in their local 
community for a duration of 20 months. The treatment of MDR-TB is complex and 
costly to both the healthcare system and the affected individuals, hence it is important 
that effective and cost-efficient models of care are adopted, particularly in resource-
constrained settings (Fitzpatrick, & Floyd, 2012; Mitnick et al., 2003). Aside from model 
of care, other factors such as the existence of comorbidities such as HIV and diabetes 
have been associated with poor treatment outcomes among MDR-TB patients (Burgos et 
al., 2018; Wells et al., 2007).  
There is evidence to support the effectiveness of the complete community-based 
model of care (Bassili et al., 2013; Ho et al., 2017; Weiss, Chen, Cook, & Johnston, 
2014) in settings other than Nigeria. There are however contextual factors in Nigeria that 
may affect the delivery of the different models of MDR-TB care. These factors include a 
generally weak health system and poor government funding of National Tuberculosis 
Program among others (WHO, 2017). There is limited evidence to establish the relative 
advantage of community-based model over the hospital-based model. A systematic 
review that compared the community-based to hospital model of care in Bangladesh, 
China, Ethiopia, Kenya, India, South Africa, Philippines, Russia, and Uzbekistan showed 
that community-based model is associated with better treatment outcomes than the 
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traditional hospital model of care (Williams et al., 2016). However, the quality of the 
studies included in the systematic review was not robust enough to establish the 
effectiveness of the community-based model of care in settings other than those 
investigated (Williams et al., 2016). Considering this, the result may not be generalizable 
to other high burden countries such as Nigeria. Different variants of community and 
hospital-based model of care are adopted in different settings, hence results obtained in 
other countries may not be applicable in all settings (Molla et al., 2017). Additionally, 
Nigeria’s community-based model of care is relatively recent and builds on global rather 
than local experience. These global settings may not be similar to the Nigerian context.  
In a study conducted in Nigeria, in which researchers reviewed treatment 
outcomes of a cohort of MDR-TB patients managed in treatment centers, researchers 
recommended the hospital-based model of care as an effective method because it 
improved treatment adherence (Oladimeji et al., 2014). However, the result of this study 
is contrary to the findings of similar studies conducted in other MDR-TB high burden 
countries (Loveday et al., 2015; Williams et al., 2016). In the same study, the association 
between HIV and treatment outcomes among MDR-TB patients was investigated; 
however, the results were inconclusive due to inadequate sample size. A similar study 
conducted in Nigeria, researchers reviewed the treatment outcome of patients managed in 
the community and reported a low rate of loss to follow up (Mbaave, Igbabul, & 
Achinge, 2016). This study was limited by a small sample size (40 patients) and the 
researchers also failed to account for outcomes at the end of the treatment period, instead 
only considering the outcomes after the intensive period of 8 months. Considering these 
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gaps in literature, there is need for further investigation to demonstrate the most effective 
treatment or care model for MDR-TB in resource-limited settings such as Nigeria and to 
determine how the existence of co-morbidities such as HIV and diabetes, among others, 
affect treatment outcomes among MDR-TB patients. 
Purpose of the Study 
The purpose of this study was to investigate the effect of model of care whether 
hospital-based or complete community-based model on the treatment outcomes of MDR-
TB patients. I also investigated the effect of other factors such as the existence of other 
diseases such as HIV and demographic factors such as gender, age and marital status on 
treatment outcomes of MDR-TB patients. The burden of MDR-TB in Nigeria makes it an 
important public health issue that heavily impacts the quality of life of those affected by 
the disease (Daniel & Osman, 2011). In light of this fact, the National TB program has 
adopted the complete community-based management of MDR-TB alongside the 
ambulatory model of care to increase the treatment capacity to manage MDR-TB 
patients.  
The treatment of MDR-TB is extensive, toxic, and expensive both to the 
healthcare system and to the individual, hence the need for a systematic evaluation of the 
effectiveness of existing models of care and some other key variables, such as the 
presence of comorbidities that may affect the outcome of the treatment. A patient-
centered approach to TB management is essential to achieving a positive outcome. 
Hence, it is critical that policies and treatment guidelines adopted by the National TB 
programs are tested empirically to establish their effectiveness and appropriateness in the 
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country’s context. A robust understanding of the factors that influence treatment 
outcomes among MDR-TB patients may be key in reducing the burden and impact of the 
disease.  
The result of this study may provide insights on how treatment outcomes among 
MDR-TB patients can be improved by addressing some of the identified risk factors that 
are associated with poor treatment outcomes (see Drobniewski et al., 2002). Most 
importantly, the result of this study may provide the evidence needed to inform policy 
changes in the management of MDR-TB patients in Nigeria particularly with regards to 
the model of care that is adopted and how care is delivered in general. Additionally, the 
findings of the study may address the existing gap in literature as it relates to the 
demonstration of the effective model of care that is feasible for managing MDR-TB 
patients in resource-limited settings like Nigeria. 
Research Questions and Hypotheses 
Research Question 1 (RQ1): Is there an association between type of treatment 
model; hospital or complete community-based, and treatment outcome among MDR-TB 
patients in Nigeria? 
Null Hypothesis (H01): There is no association between type of treatment model 
and treatment outcomes among MDR-TB patients in Nigeria. 
Alternate Hypothesis (Ha1): There is an association between type of treatment 
model and treatment outcomes among MDR-TB patients in Nigeria. 
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Research Question 2 (RQ2): Are co-morbidities such as HIV associated with poor 
treatment outcomes among MDR-TB patients in Nigeria? 
Null Hypothesis (H02): There is no difference in treatment outcomes between 
patients with co-morbidities and those without in Nigeria. 
Alternate Hypothesis (Ha2): There is a difference in treatment outcomes between 
patients with co-morbidities and those without in Nigeria. 
Research Question 3 (RQ3): Is type of treatment model associated with survival 
outcomes among MDR-TB patients in Nigeria? 
Null Hypothesis (H03): There is no difference in survival outcomes between 
patients enrolled on the two different models of care in Nigeria. 
Alternate Hypothesis (Ha3): There is a difference in survival outcomes between 
patients enrolled on the two different models of care in Nigeria. 
Research Question 4 (RQ4): Are demographic factors such as age, gender, and 
marital status associated with treatment outcomes among MDR-TB patients in Nigeria? 
Null Hypothesis (H04): There is no association between demographic factors such 
as age, gender, marital status, and treatment outcomes among MDR-TB patients in 
Nigeria. 
Alternate Hypothesis (Ha4): There is an association between demographic factors 
such as age, gender, marital status, and treatment outcomes among MDR-TB patients in 
Nigeria. 
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Theoretical Foundation for the Study 
The key theoretical framework for this study was the health belief model (HBM). 
The HBM was originally developed in the 1950s by social psychologists to improve the 
uptake of free tuberculosis screening program (Hochbaum, 1958). Researchers use the 
model to explain how health behaviors are shaped by individual factors. The key 
constructs of HBM include individual factors such as perceived susceptibility, perceived 
severity to a disease, perceived barriers and benefits to achieving behavior change, and 
the individual’s self-efficacy (Glanz & Bishop, 2010). The HBM focuses on the 
individual’s innate ability to achieve behavior change by targeting the perceptions and 
beliefs about the disease and emphasizing the benefits that will accrue if behavior change 
is achieved. Researchers have used the HBM to address public health issues that are 
driven by negative health behaviors (Glanz & Bishop, 2010). These include smoking, 
obesity, and HIV, among others. The HBM is therefore applicable to address other health 
challenges and issues that may be driven by human behaviors. In the case of MDR-TB 
management, adherence to treatment regimen is a key component of patient management 
and can impact heavily on the outcome of treatment (Kliiman & Altraja, 2009). 
The HBM can be applied to enhance adherence to treatment and is therefore appropriate 
for explaining the complex pathways between MDR-TB patient enrollment and the 
outcomes at the end of the treatment period. The model provides a framework that can 
guide the development of health education programs toward improving treatment 
adherence (Glanz & Bishop, 2010). For the purpose of this study, I used the HBM to 
describe the effect of patients’ adherence pattern on treatment outcomes and how self-
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efficacy influenced these behavioral patterns. Similarly, I applied the model to explain 
individual variables that acted as modifying factors between treatment enrollment and 
outcomes. The modifying factors for this study included gender, age, and marital status as 
shown in Figure 1. Because the main constructs of the health belief model emphasize 
self-efficacy and self-assessment of risk as enablers of positive behavior changes, it 
provided a useful framework for describing the actions and policies needed to develop a 
patient-centered and effective model of care for the management of MDR-TB patients.  
 
   Individual factors                            Modifying factors                Likelihood of action 
 
Figure 1. Conceptual framework of Health Belief Model. From “Effect of Health Belief 
Model based intervention on promoting nutritional behaviors about osteoporosis 
prevention among students of female middle schools in Isfahan, Iran.” by M. Ghaffari, A. 
Esmaillzadeh, E. Tavassoli, & A. Hassanzadeh, 2012, Journal of Education and Health 
Promotion, 1(1), p. 14. 
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Nature of the Study 
In this study, I used a quantitative research method. I conducted a register based 
cross-sectional study of routinely collected National Tuberculosis Program data for the 
period of January 2013 to December 2014. The dependent variable for the study was the 
treatment outcome for the MDR-TB patients, which I reclassified as successful or 
unsuccessful from the many categories of outcomes defined by the TB program 
(treatment completed, cured, loss to follow up, died, treatment failure). The predictor 
variables included the model of care, existence of co-morbidities and demographic 
factors specifically age, gender, and marital status. 
I included all clients with complete records of the treatment outcome in the study 
and prepared a checklist to extract data from patient records. I selected patients’ records 
from the two models of care adopted in Nigeria. I drew the study population from 
patients enrolled for treatment between 2013 and 2014 through the National Tuberculosis 
Program. The study included patients managed in the treatment centers using the 
ambulatory approach and those managed in the communities. I conducted statistical 
analysis to determine if type of treatment model is a predictor of treatment outcomes 
among MDR-TB patients in Nigeria. Other predictor variables included the existence of 
co-morbidities such as HIV and demographic factors such as age, gender, and marital 
status. 
Literature Search Strategy 
The library databases and search engines I used for the literature review included 
EBSCO, Science Direct, PubMed, MEDLINE, AJOL and PsycARTICLES, PsycINFO, 
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and CINAHL databases. I also retrieved articles from Google Scholar and useful websites 
such as those of World Health Organization. I accessed databases through the Walden 
University Library. The search terms I used included multidrug resistant, multi-drug 
resistant, MDR-TB, MDR-TB and treatment models, drug resistant TB, MDR-TB and 
treatment outcomes, MDR-TB, and comorbidities.   
The scope of the literature included papers published from 2010 until 2018 as 
well as a few papers published before 2010. I included mainly peer-reviewed studies in 
the literature review, but also included some non-peer-reviewed studies. There is limited 
current research on the subject area, hence all literature available was included as well as 
programmatic reports, conference reports, and non-peer-reviewed journals. 
Literature Review Related to Key Variables and Concepts 
Population and Settings 
The population of Nigeria is the largest in Africa. As of 2013, it was estimated to 
be 173 million people across 36 states and the Federal Capital Territory (FCT; (WHO, 
2015b). The Nigerian population is fairly young, with a median age of 18 years (National 
Population Commission & ICF International [NPC & ICF], 2014). The country has a 
large land mass and a diverse geography with both uplands and lowlands. Nigeria is 
located on the west coast of Africa between latitudes 4º16' and 13º53' north and 
longitudes 2º40' and 14º41' east (NPC & ICF, 2014). The country is situated on an 
estimated 923,768 square kilometers of land extending from the Gulf of Guinea on the 
Atlantic coast in the south to the borders of the Sahara Desert in the North (NPC & ICF, 
2014). The geography boundaries are shared with the republics of Niger and Chad in the 
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north, the Republic of Cameroon on the east, and the Republic of Benin on the west. 
Nigeria is divided geographically into the north and the south. There is a further 
subdivision into six geopolitical zones, namely: the Southwest, South-south, Southeast, 
Northeast, Northwest, and the Northcentral. The climate of the country is mainly tropical 
and characterized by the wet southerly winds and the cold, dry, and dusty northeasterly 
winds. The country has a growing agricultural sector, but the economy is largely 
dependent on the exportation of crude oil. Nigeria is blessed with a diversity of ethnic 
groups and cultures. There are over 250 ethnic groups and more than 500 languages 
(National Population C & ICF, 2014). The main languages are Yoruba, Igbo, and Hausa 
while English is used to communicate across the different ethnic groups. The majority of 
the people are either Christians or Muslims.  
The country has a weak health system and there is no universal health coverage 
(PharmAccess Foundation, 2014). Only 6% of the country’s GDP is spent on health and 
healthcare (WHO, 2015b). There are huge disparities in the way healthcare is delivered 
across the country with the majority of the health workforce being in the southern part of 
the country (NPC & ICF, 2014). 
 MDR-TB profile in Nigeria. Nigeria is among the highest TB burden countries 
in the world. In 2017, Nigeria was ranked highest in Africa and fourth in the world for 
TB burden (WHO, 2016). The country has also been classified as a high burden MDR-
TB country. In high-burden settings such as Nigeria, interpatient transmission is the main 
source of MDR-TB infection (Onyedum, Alobu, & Ukwaja, 2017). The HIV/AIDS 
epidemics in Nigeria may have also fueled the increasing trend observed in the burden of 
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MDR-TB in the country as indicated by the results of the 2012 National Drug Resistant 
Tuberculosis Prevalence survey. Based on the report of the survey, 2.9% of MDR-TB 
cases were from new TB patients and 14.3% were from previously managed TB patients 
(Nigeria Federal Ministry of Health, 2012). The growing burden of the disease calls for 
expansion of the treatment capacities. As at 2014, there were nine functional MDR-TB 
treatment centers spread across seven states (Avong et al., 2015). Based on a review of 
the programmatic report, there are currently 15 treatment centers in the country, with 390 
Xpert MTB/RIF sites to facilitate early diagnosis of MDR-TB among patients in high risk 
groups across all the states in the country. 
Challenges of the MDR-TB program in Nigeria. There are a number of 
challenges hampering the effective control of MDR-TB in Nigeria. These include weak 
political will and over-reliance on external funding support for the MDR-TB program 
(USAID, 2016). Other issues include a weak healthcare system and poor infrastructural 
capacity to support the diagnosis and management of the disease (Aliyu et al, 2010). 
Gidado (2018) showed that installation of Xpert MTB/RIF machine which is the first line 
of diagnosis for MDR-TB in the country requires adequate power supply, laboratory 
space, and capable staff for the machine to be optimally utilized. However, these 
requirements are rarely met at the primary health care facilities and most of the secondary 
and tertiary facilities are unable to provide uninterrupted power supply (Mustapha et al., 
2015). Researchers have recommended installation of solar panels; however, this requires 
a lot of resources which may not be readily accessible through internal funding. Bed 
spaces for hospital-based management of MDR-TB patients are inadequate and the 
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community-based model of care is new enough that unresolved issues are hampering 
rapid scale-up across the states of the country. Other challenges include lack of technical 
expertise in-country to maintain the Xpert MTB/RIF machines, poor health workers’ 
attitude, high rates of loss to follow up, and an ever increasing gap in cases detected and 
those enrolled for treatment (Abdurrahman et al., 2014; Isara & Akpodiete, 2015; 
Mustapha et al., 2015). The gap in case detection and enrollment for care in 2014 was 
over 370 MDR-TB patients (USAID, 2016). According to USAID (2016), this gap has 
increased steadily over the years to about 500 MDR-TB patients in 2017.  
MDR-TB treatment guidelines in Nigeria. The National Guidelines for 
management of MDR-TB in Nigeria is in line with the WHO’s recommended MDR-TB 
guidelines. The diagnosis of the disease commences with the identification of a 
presumptive MDR-TB case (Falzon et al., 2011). A presumptive MDR-TB patient may 
be anyone who has come in contact with a confirmed MDR-TB patient and who shows 
symptoms of TB, a patient whose AFB result is smear positive when smear is repeated at 
the end of month three of treatment with anti-TB medications, all previously treated drug-
susceptible TB patients, relapse cases, patients receiving treatment after long periods of 
interruption, other previously treated patients, and persons with unknown history of TB 
(NTLP, 2013). Persons considered to be vulnerable to MDR-TB include all persons with 
smear negative AFB result who still show symptoms of TB after 1 week of 
administration of broad spectrum antibiotics, persons living with HIV virus who present 
with symptoms of TB, all health care staff who present with symptoms of TB, all 
children who present with symptoms of TB, and all persons with symptoms suggestive of 
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extra-pulmonary TB in which specimen could be collected for Xpert MTB/RIF testing 
such as collection of cerebrospinal fluid (CSF) for examination as in TB meningitis 
(NTLP, 2013).  
Treatment delivery models include the ambulatory model of care as well as the 
complete community-based model. The ambulatory model entails the initial 
hospitalization for the 8-month period of the intensive phase while the ambulatory 
treatment is provided to patients at the nearest TB treatment clinic for the remaining 
duration of treatment (Falzon et al., 2011). Specialized medical services are also provided 
to the patient as at when required. The complete community model entails the 
commencement of patients on treatment in their homes with the assistance of a treatment 
supporter (NTLP, 2013; Williams et al., 2016). The medications used in the management 
of MDR-TB include kanamycin or capreomycin, pyrazinamide, cycloserine, 
levofloxacin, and prothionamide (NTLP, 2013). The newly adopted shorter regimen 
entails a 4 to 6-month intensive phase of treatment with a combination of kanamycin, 
moxifloxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid and 
ethambutol, followed by a 5-month continuation phase containing moxifloxacin, 
clofazimine, ethambutol, and pyrazinamide (NTLP, 2013). Based on the resistant profile, 
newer formulations and medications in the same of class of antibiotics can be used. 
National Treatment Protocol 
The treatment protocol for MDR-TB in Nigeria is line with the WHO guidelines 
for treating MDR-TB (Falzon et al., 2011). In the years researchers reviewed for the 
study, the National MDR-TB treatment protocol entails 6-8 months of intensive phase 
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with the administration of oral medications and injectable and a 12-month continuation 
phase with the use of only oral medications. The standardized treatment regimen includes 
kanamycin or amikacin, levofloxacin, prothionamide, cycloserine, and pyrazinamide 
(with pyridoxine). All patients are taken through a baseline investigation that tests for 
kidney and liver functions, audiometry among others. During treatment, patients are 
monitored monthly using sputum smear microscopy and culture examinations. 
Reporting of Treatment Outcomes for Tuberculosis & Drug-Resistant TB 
Treatment outcome analysis of patients managed for TB including MDR-TB is 
done using a cohort approach. The cohort review describes the outcome analysis of the 
group of patients enrolled for treatment over a specific period of time, usually three 
months. These patients are reviewed at about 6-9 months after completion of treatment. 
This is to ensure that all patients registered within the cohort period are given the 
opportunity to complete their treatment and to account for any challenges for data 
collection and collation. Hence, outcome evaluation for the cohorts of MDR-TB patients 
registered in 2013 was done between 2014 and 2015 while those registered in 2014 were 
evaluated between 2015 and 2016. The outcome evaluation is done on a case by case 
basis and outcome is assigned to each of the patients to complete the patient-level data 
collected for the treatment period. Upon completion of the cohort review, outcomes are 
included as a composite of the MDR-TB patient level data. 
Description of existing models of MDR-TB management. The models of care 
have different variants across countries; hence comparison of effectiveness as measured 
by successful treatment outcomes may not be possible. The extent of decentralization 
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also varies across settings; some countries employ complete community or home-based 
models of care while many adopt the ambulatory model of care as recommended by 
WHO whereby patients spend the intensive phase of treatment in the hospitals and the 
continuation phase is managed in the community (Molla et al., 2017). Researchers agree 
that there is a need for more empirical evidence from sub-Saharan African countries to 
support the effectiveness of decentralized model of care in resource-limited settings (e.g., 
Molla et al., 2017; Schnippel et al., 2015; Weiss et al., 2014). Decentralization of care as 
described in the literature describes the management of MDR-TB patients in their own 
homes by involving trained health workers or linking the patients to specific health 
facilities where their treatment can be monitored and adverse drug reactions managed 
(Molla et al., 2017). The approach also involves the application of injections by the 
health workers for models where complete home-based care is implemented. In this case, 
patients are managed completely in their community as against the ambulatory approach 
that involves partial hospitalization during the intensive phase of treatment (Burtscher et 
al., 2016; Molla et al., 2017). Evidence from Ethiopia and South Africa shows some 
merit in adopting the decentralized or home-based model of care for managing MDR-TB 
patients (Brust et al., 2012; Loveday et al., 2015; Molla et al., 2017). Favorable treatment 
outcomes were reported for community-based model of care from similar studies that 
compared community-based and hospital-based models of care in different settings 
(Weiss et al., 2014; Williams et al., 2016). Qualitative evidence suggests that patients 
prefer to be treated at home because of psychosocial support from family members and 
the fact that they can continue to earn a living (Bieh, Weigel, & Smith, 2017; Burtscher et 
21 
 
al., 2016; Horter et al., 2014) There is also evidence to suggest the association of 
socioeconomic barriers with hospital-based model of care but not with home-based care 
model (Horter et al., 2014).  
Involvement of community health workers and trained volunteers in the home-
based management of MDR-TB patients was recommended in Ethiopia, South Africa, 
Peru and Myanmar among others (Horter et al., 2014; Molla et al., 2017; Shin et al., 
2004; Wai et al., 2017; Weiss et al., 2014; Williams et al., 2016). TB-related stigma has 
been associated with poor treatment adherence. Community health workers have been 
found to be relevant in addressing stigma through health education (Molla et al., 2017). 
Evidence to support decentralization of MDR-TB management. MDR-TB is a 
major threat to the effective control of the TB epidemics (Brust et al., 2012). The ever-
increasing burden of the disease calls for immediate public health responses that can halt 
its transmission while providing optimal care for those already affected (Molla et al., 
2017). There is ample evidence to suggest the need for scaling up MDR-TB treatment 
services, particularly in high burden countries, to meet the overwhelming rise in case 
detection (Brust et al., 2012; Loveday et al., 2015; Molla et al., 2017; Taneja, 2017).  
Scale up of treatment services in resource-limited settings require innovation and 
ongoing investigations to determine the optimal model of care. Researchers have found 
the hospital-based model of care to be unsustainable in the face of the rising burden of 
MDR-TB incident cases in high-burden countries such as India, Nigeria, China, and 
South Africa, among others (e.g., Brust et al., 2012; Horter et al., 2014; Salje et al., 
2014).  
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Through a systematic review of the cost effectiveness of models of care in 
Estonia, Peru, the Philippines, and Tomsk, Fitzpatrick and Floyd (2012) found that 
outpatient or community-based model of care incurred lower costs than hospital-based or 
in-patient model of care. Their findings may, however, not be directly applicable to the 
Nigerian setting due to contextual differences between the African region and the 
European and Asian settings which were the focus of the study. Musa, John, Habib, and 
Kuznik (2016), who conducted their study in Nigeria, also confirmed that community-
based model of care is more cost effective than the hospital-based model. Bassili et al.’s 
(2013) systematic review, in which they evaluated the effectiveness of the hospital-based 
and the ambulatory model of care in a wide range of settings across 22 countries 
including South Africa, resulted in findings that the hospital-based model was not 
significantly associated with better treatment outcomes than the ambulatory model.  
Considering the limited treatment capacities in many high burden countries and 
the fact that only 16% of the estimated number of MDR-TB cases among TB diagnosed 
globally have access to treatment, this finding favors the adoption of the ambulatory 
model of care (WHO, 2017). This finding provided the evidence that backed the 
recommendation of the ambulatory model by the World health Organization (Bassili et 
al., 2013). Also, in a systematic review conducted to determine the effectiveness of 
decentralized (community-based) model of care in comparison with centralized or 
hospital-based model of care, researchers found that patients were more likely to have 
treatment success when treated using the decentralized model (Ho et al., 2017). Ho et al. 
explained that the better treatment outcome recorded among patients managed using the 
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decentralized model may be explained by improved adherence as a result of greater social 
support from family members and wider social networks. The effectiveness of 
decentralization of MDR-TB care as documented in many resource-constraint settings 
such as India, South Africa and Ethiopia provided the basis for implementing ambulatory 
and community-based models of care in countries with similar settings (Brust et al., 
2012; Furin et al., 2011; Loveday et al., 2015; Molla et al., 2017; Taneja, 2017). 
However, lessons learned in countries may be context specific and may not apply in other 
country settings. Moreover, hospital-based models of care were found to be associated 
with higher rates of loss to follow up than decentralized models in a few countries (Ho et 
al., 2017). 
Evidence that supports hospital-based management of MDR-TB. There are 
some arguments in favor of hospital-based management of MDR-TB, these include the 
need to administer and monitor complex, toxic drug regimens and to limit the community 
spread of drug-resistant TB (Heller et al., 2010). However, many MDR-TB patients are 
not detected early and therefore remain untreated and infectious long before they are 
hospitalized, hence, early detection may be a more effective way to contain the spread of 
the infection than patient isolation in hospitals (Heller et al., 2010; Van Cutsem et al., 
2016). In addition, hospital-based models may expose patients and health workers to 
nosocomial infections (Van Cutsem et al., 2016). In the same vein, MDR-TB patients 
admitted in hospitals may infect the health workers who relate closely with them in the 
course of providing care, as well as visiting family members and friends (Luyirika et al., 
2012; Van Cutsem et al., 2016). In light of this, infection control strategies are required at 
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both the health facility and community levels (Heller et al., 2010; Ho et al., 2017). Also, 
Oladimeji et al. (2014) conducted a study in Nigeria and found lower loss to follow up 
among MDR-TB patients managed using the hospital-based model of care. Skrahina et al. 
(2013) conducted in Belarus with similar results, finding higher loss to follow up among 
MDR-TB patients during the outpatient treatment phase. However, this is contrary to the 
findings of studies conducted in Peru and South Africa which suggested that hospital-
based management of MDR-TB is not associated with improved treatment adherence 
relative to the community-based model of care (Heller et al., 2010; Mitnick et al., 2003). 
This may be explained by the social and economic costs associated with hospitalizing 
MDR-TB patients which may include loss of income and loss of, or reduced social 
support from relatives and friends (Baleta, 2007; Heller et al., 2010). Also, patients may 
feel confined in hospital settings and may abscond from treatment as a result of the 
prison-like feeling of being hospitalized for the duration of MDR-TB treatment (Baleta, 
2007). 
Management of adverse drug reactions is key to the successful outcome of MDR-
TB treatment (Akshata & Chakrabarthy, 2016). This is because of the complexity and 
toxic nature of the medications used in the management of MDR-TB (Dela, Tank, Singh, 
& Piparva, 2017). Some have argued that the management of adverse drug reactions 
associated with MDR-TB treatment may be more effective in hospital settings and this 
expertise may be lacking under the community-based model of care (Dela et al., 2017; 
Heller et al., 2010). However, a study that compared the ambulatory and hospital-based 
model of care indicated that patients managed in the hospital suffered more adverse drug 
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reactions than the patients managed using the ambulatory model of care (Kalandarova et 
al., 2016). 
Factors associated with poor treatment outcomes in MDR-TB management. Several 
authors have identified predictors of poor treatment outcomes among MDR-TB patients 
(i.e., Aibana et al., 2017; Kliiman & Altraja, 2009; Li, Ge, Shen, & Wei, 2016; Mohd 
Shariff, Shah, & Kamaludin, 2016; Schnippel et al., 2015). These predictors include 
previous treatment history, age greater than 45 years old, sputum smear positive result at 
time of diagnosis, migrant status, distance from the patient’s home to the related TB 
hospital, and co-morbidities such as HIV and diabetes (Li et al., 2016). Wai et al. (2017) 
also identified age greater than 55 years old, anemia, and weight less than 45 kg as risk 
factors for poor treatment outcomes among MDR-TB patients. Another study conducted 
in Belarus, however, produced results indicating young age, HIV, history of 
incarceration, unemployment, and homelessness as predictors of poor treatment outcomes 
among MDR-TB patients (Skrahina et al., 2013). Researchers have also identified 
diabetes as a predictor of poor treatment outcome (Muñnoz-Torrico et al., 2017). Also, 
being HIV positive and not on ART was found to be associated with poor treatment 
outcomes among MDR-TB patients although the sample size of the study was small 
(Aibana et al., 2017; Kliiman & Altraja, 2009). A similar study conducted in Lesotho 
demonstrated the effectiveness of managing HIV positive MDR-TB patients using the 
community-based model of care (Satti et al., 2012). Predictors of successful treatment 
identified include knowledge about the disease, adherence to treatment and dedicated 
health workers (Napirah, Wandira, & Aulia, 2017). A study conducted in India to study 
26 
 
the association between gender, marital status and treatment outcome of MDR-TB 
patients was inconclusive (Patel et al., 2016). This may be due to small sample size and 
suboptimal study design. 
Operational Definitions 
Ambulatory model of care: involves in-patient management in the hospital under 
the close supervision of health workers for the duration of the intensive phase of about 6 
months and out-patient management for the rest of the treatment period (WHO, 2014b.   
Complete community or home-based model of care: involves management of the 
patients in their home or social settings throughout the duration of treatment (USAID, 
2017; Falzon et al., 2011). In the Nigerian context, this involves the use of treatment 
supporters and linkage to nearby health facilities where injections can be provided and 
adverse drug reactions and other treatment components monitored closely by the health 
worker (Mbaave, Igbabul & Achinge, 2016).  
Cure: treatment completed as recommended by the national policy without 
evidence of failure and in which three or more consecutive cultures taken at least 30 days 
apart are negative after the intensive phase (WHO, 2014a).  
Death: death from any cause (TB or non-TB) during the course of chemotherapy 
(WHO, 2014a).  
Failure: treatment terminated or need for permanent regimen change of at least 
two anti-TB drugs because of lack of conversion by the end of the intensive phase or 
bacteriological reversion in the continuation phase after conversion to negative, or 
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evidence of additional acquired resistance to fluoroquinolones or second-line injectable 
drugs, or adverse drug reactions (WHO, 2014a).  
Loss to follow up: describes any patient who had interrupted treatment for two 
consecutive months or more and who never returned for treatment. 
Successful treatment outcome: refers to a patient being cured or treated.  
Transferred out: refers to patients transferred out of the country.  
Treatment outcome: outcomes that include cure, treatment completed, died, 
transferred out, and loss to follow (WHO, 2014a).  
Treatment completed: completion of the treatment course without bacteriologic 
documentation of cure while treatment success is described as those who completed 
treatment or were cured (WHO, 2014a).  
Unsuccessful treatment outcome: refers to any result other than cure or treatment, 
including loss to follow up, death, and treatment failure, but not including transferred out 
patients, who will not be considered in the analysis.  
Assumptions 
For the purpose of this study, I made assumptions that all patient-level data 
received from the National Tuberculosis and Leprosy Control Program are accurate and 
complete information of the patients. Furthermore, I assumed that the health workers who 
collected the data were objective and collected accurate and complete information from 
the patients without manipulating or entering false data into the data management 
systems. I also assumed that the patient provided correct information and complete data 
about the state of their health and the presence of all other diseases they may suffer from. 
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Also, all patients who died during the MDR-TB treatment were assumed to have died as a 
result of the disease, regardless of the actual cause. This is line with the definition of 
death as a treatment outcome in the course of TB treatment (WHO, 2014a). This is a 
general assumption on the TB program because it is often difficult to determine the cause 
of death. These assumptions about the quality of the data and the cause of death may 
have affected the results and inferences made from the study.   
Scope and Delimitations 
For the purpose of this study, I employed a quantitative approach without 
exploring the experiences and perspectives of the patients about the treatment and how 
this may have impacted the observed treatment outcomes. My investigation was focused 
on the relationship between model of care and treatment outcomes, in which case, models 
of care was limited to just community-based and the ambulatory models and did not 
account for variants that may exist such as some patients that may have to be admitted in 
hospitals in the course of their treatment due to adverse drug reactions or other causes of 
illness while being classified as patients managed in the community. 
Existence of co-morbidities only included HIV. I did not consider other health 
conditions such as hypertension, heart diseases, malaria, typhoid, and other common 
health conditions in the country as part of the investigation. While the scope of the study 
did not include these illnesses, they may, nonetheless, be associated with the observed 
treatment outcomes. I did not investigate health workers’ attitudes, or the kind of social 
support provided to the patients, although these factors may have had an effect on the 
observed treatment outcomes. I included only patients managed in Nigeria between 2013 
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and 2014. This is because the community-based model of care became fully operational 
in Nigeria in 2013 and I could not determine when the cohort analysis of patients beyond 
2014 would be available at the time I was designing the study.   
Significance, Summary, and Conclusions 
The purpose of this study was to develop a better understanding of the factors that 
result in poor treatment outcomes among MDR-TB patients. The key objective of the 
study was to determine if the model of care (ambulatory and complete community-based 
or out-patient), existence of co-morbidities, particularly HIV and other demographic 
characteristics such as age, marital status and gender, influence the treatment outcomes 
observed in MDR-TB patients. A robust understanding of the factors that influence 
treatment outcomes among MDR-TB patients may be key in reducing the burden and 
negative impact of the disease. The results of this study provided insights on how 
treatment outcomes among MDR-TB patients can be improved by addressing some of the 
identified risk factors that result in poor treatment outcomes (see Drobniewski et al., 
2002). Most importantly, the results of this study provided evidence necessary to inform 
policy changes in the management of MDR-TB patients in Nigeria particularly with 
regards to the model of care that is adopted and how care is delivered in general. 
Additionally, the findings of the study helped fill the existing gap in literature as it relates 
to the demonstration of the effective and optimal model of care that is feasible for 
managing MDR-TB patients in resource-limited settings like Nigeria. The implication for 
social change is that Nigeria may improve the quality of treatment provided to MDR-TB 
patients by ensuring that the more effective model of care is adopted. Also, this study 
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provided information about the effect of HIV and demographic factors such as age, 
gender, and marital status on treatment outcomes among MDR-TB patients. A deeper 
understanding of the relationship between these factors may inform the development of 
policies and guidelines that can address existing gaps in the quality of care provided to 
MDR-TB patients. Other implications for social change include the possibility of more 
gender-sensitive treatment guidelines, adaptation of specific treatment models for 
different age categories, and special provisions for the management of co-morbidities in 
MDR-TB control programs. 
Several factors have been associated with poor treatment outcomes among MDR-
TB patients. These factors include model of care, age, gender, existence of co-morbidities 
such as HIV, and type of social support provided to the patients among others (Li et al., 
2016). Researchers have investigated the effect of model of care on treatment outcomes 
in countries such as South Africa, Ethiopia, India, Peru, among others (i.e., Loveday et 
al., 2015; Mitnick et al., 2003; Molla et al., 2017; Patel et al., 2016). The results of these 
studies suggested that community or home-based models of care may be a better 
treatment option based on the more favorable treatment outcomes observed. Researchers 
have also used qualitative evidence to support the superiority of the home-based model of 
care over the hospital-based model of care (Burtscher et al., 2016; Horter et al., 2014). 
Little empirical evidence has been generated through quantitative methodology, and 
quantitative studies often have small samples sizes. The quality of a few of these studies 
was also suboptimal; hence the need for a more robust study methodology to determine 
the relationship between model of care and treatment outcomes among MDR-TB patients 
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(Ho et al., 2017; Loveday et al., 2015; Oladimeji et al., 2014). Through the literature 
review, I only identified a few studies that were conducted in resource limited settings 
such as Nigeria (e.g., Mbaave, Igbabul, & Achinge, 2016; Oladimeji et al., 2014). 
Oladimeji et al. (2014) conducted their study in Nigeria before the adoption of the 
community based model of care and suggested that hospital-based model of care was 
linked to better treatment adherence. Their evidence was not compelling and was not 
consistent with the available evidence in literature, such as that from Ho et al. (2017), 
Loveday et al. (2015), Molla et al., (2017) and Williams et al. (2016). A few studies also 
assessed the cost effectiveness of the different models of care employed in the 
management of MDR-TB patients (e.g., Bassili et al., 2013; Fitzpatrick & Floyd, 2012; 
Musa et al., 2016). The findings of most of these studies showed community-based model 
of care to be more cost effective than hospital based.  
Therefore, through this study, I sought to investigate the relationship between 
model of care and treatment outcomes among MDR-TB patients in a resource-limited 
setting and a country with high HIV burden such as Nigeria. The findings of this study 
provided empirical evidence needed to determine which of the models of care currently 
employed in Nigeria is more effective to enable the optimization of patients’ quality of 
care. Also, through this study I sought to investigate how the existence of co-morbidities 
such as HIV interfere with treatment outcomes among MDRTB patients in Nigeria. This 
is important because of the inherent weaknesses in the country’s healthcare system 
especially lack of universal health coverage and mostly out of pockets expenditures for 
healthcare (Tadesse, Demissie, Berhane, Kebede, & Abebe, 2013).  
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Section 2: Research Design and Data Collection 
Introduction 
Multidrug resistant tuberculosis (MDR-TB) has become increasingly prevalent in 
countries such as China, India, and Nigeria, and others (World Health Organization 
[WHO], 2016). The increasing trend in the burden of MDR-TB has made it necessary to 
increase the capacities of high-burden countries to manage patients affected by the 
disease. The burden of MDR-TB in Nigeria makes it an important public health issue that 
impact heavily on the quality of life of those affected by the disease (Daniel & Osman, 
2011).  
In light of this fact, the National TB program has adopted the complete 
community-based management of MDR-TB alongside the ambulatory model of care to 
increase the treatment capacity to manage MDR-TB patients. Against this backdrop, 
there is an urgent need for the rapid scale-up of MDR-TB treatment services in high 
burden countries such as Nigeria. Currently, there are limited studies to establish the 
effectiveness of community-based model of care for MDR-TB patients in Nigeria. 
Through this study, I sought to demonstrate the effect of the model of care and existence 
of co-morbidities such as HIV on treatment outcomes among MDR-TB patients.  
The treatment of MDR-TB is extensive, toxic, and expensive both to the 
healthcare system and to the individual hence the need for a systematic evaluation of the 
effectiveness of existing models of care and some other key variables, such as the 
presence of comorbidities that may affect the outcome of the treatment. A patient-
centered approach to TB management is essential for achieving a positive outcome. 
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Hence, it is critical that policies and treatment guidelines adopted by the National TB 
programs are tested empirically to establish their effectiveness and appropriateness in the 
country’s context. A robust understanding of the factors that influence treatment 
outcomes among MDR-TB patients may be key in reducing the burden and impact of the 
disease.  
The results of this study may provide insights on how treatment outcomes among 
MDR-TB patients can be improved by addressing some of the identified risk factors that 
are associated with poor treatment outcomes (see Drobniewski et al., 2002). Most 
importantly, the result of this study may provide the evidence needed to inform policy 
changes in the management of MDR-TB patients in Nigeria particularly with regards to 
the model of care that is adopted and how care is delivered in general. Additionally, the 
findings of the study may address the existing gap in literature as it relates to the 
demonstration of the effective model of care that is feasible for managing MDR-TB 
patients in resource-limited settings like Nigeria.  
In the previous section, I described the existing evidence in literature that 
compares the different models of care, their effect on treatment outcomes of MDR-TB 
patients, other predictors of successful or unsuccessful treatment outcomes. In the 
previous section, I also described the scope of the study, the operational definitions of the 
dependent and independent variables, and the assumptions and limitations of the study.  
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Research Design and Rationale 
For the purpose of this study, I employed a quantitative approach to investigate 
the effect of model of care whether hospital-based or community-based on treatment 
outcomes of MDR-TB patients. Other researchers have employed both qualitative and 
qualitative approaches to investigate and explore the effect the model of MDR-TB care 
has on the patients and their treatment outcomes (e.g., Bieh et al., 2017; Brust et al., 
2012; Ho et al., 2017; Horter et al., 2014; Loveday et al., 2015; Molla et al., 2017; 
Williams et al., 2016). In this study, I employed a cross-sectional design to investigate the 
factors that are associated with poor treatment outcomes among a retrospective cohort of 
MDR-TB patients. Factors I investigated included model of care, existence of other 
diseases (specifically HIV), age, gender, and marital status.  
A qualitative approach was not suitable for this study because it would not have 
provided the information needed to determine the empirical association between 
treatment outcomes and the factors or variables that are being investigated. It may 
however have provided insight into the perspectives of the patients and health workers. 
For instance, Bieh et al. (2017) conducted a study in Port Harcourt, Nigeria to explore the 
perspectives of patients and health workers on the hospital-based model of care. I 
determined that the retrospective cohort design was suitable for this study because of my 
desire to investigate the degree of association or relationship between treatment outcomes 
among MDR-TB patients, model of care, and other key predictor variables. A 
35 
 
randomized control design would have been most suitable to determine causality and 
therefore provide the highest level of evidence to support the best model of care for 
MDR-TB (see Akobeng, 2005). However, I utilized secondary data for this study; 
therefore, it was impossible to randomly assign persons to different types of treatment. 
For this reason, I chose the retrospective cohort design. The dependent variable was the 
treatment outcome, which I classified into two broad categories, successful and 
unsuccessful. I also considered survival outcomes after treatment whether dead or alive 
as another dependent variable in the data analysis. The independent or predictor variables 
included model of care, existence of co-morbidities, age, gender, and marital status. I 
conducted several bivariate analyses in order to determine the association between the 
dependent variable and predictor or independent variables. Additionally, I conducted 
multivariate analyses for each of the combination of variables to establish whether the 
group of two variables formed a more significant predictor than one variable alone (see 
Rencher, 2012).  
The scope of this study did not include the effect of adverse drug reactions on 
treatment outcomes. Due to time constraint, I did not validate the secondary data used for 
the analysis in the field for correctness and completeness. I assumed that the data quality 
control mechanisms of the National Tuberculosis, Buruli Ulcer and Leprosy Control 
Program (NTBLCP) were optimal and that the data were entered correctly and 
completely at the point of collection. I managed missing information at the analysis stage. 
36 
 
Methodology 
The study was based on the analysis of secondary data. The data were accessed 
from the NTBLCP. I collected the data through the institutions’ electronic data 
management system referred to as the e-TB manager. I exported the data to an excel 
template and then transferred to SPSS version 24 for analysis. Extraction of patient-level 
information was done serially until the calculated sample size was achieved. I excluded 
patients with no treatment outcome computed at the time of the study from the analysis. I 
also excluded patients with incomplete information and those under the age of 6 years 
from the analysis. It was impossible to determine the model of care applied per patient 
through this electronic management system, hence I triangulated the extracted patient-
level data with state-level data collected by the state’s TB program that managed the 
patients. In order to achieve this, I contacted the state program managers through the 
Monitoring and Evaluation Manager of NTBLCP to verify the model of care applied for 
each of the patient included in the study. I deidentified the information of the patients at 
the point of transmission by the states and NTBLCP. I accomplished the deidentification 
mostly via emails to enable the transmission of verifiable data regarding the model of 
care to which patients were enrolled.  
Population 
The study population include MDR-TB patients who were enrolled for treatment 
in Nigeria between 2013 and 2014. I chose this period because the community 
management of MDR-TB commenced fully in Nigeria in 2013 hence data for this period 
enabled a comparison between the two models of care that is currently being employed to 
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manage MDR-TB patients in Nigeria (see Mbaave, Igbabul & Achinge, 2016). I did not 
include years after 2014 in the study because the treatment of MDR-TB before the 
commencement of the shorter regimen in 2017 took an average of 20 months. For this 
reason, the cohort analysis, including the outcome of treatment which is the dependent 
variable I intended to evaluate, may not have been be available for patients managed in 
Nigeria after 2014 at the time I was conducting this study. The estimated number of new 
MDR-TB patients in 2014 was 21,000, of which only 800 cases were detected and about 
50% enrolled in treatment (USAID, 2016). The number of patients enrolled for treatment 
in 2013 was similar to the figure reported for 2014 (USAID, 2016). All MDR-TB patients 
were eligible except children from the age of 6 years and lower. I did not include children 
because of factors that can affect their treatment outcomes that I did not consider in this 
study. These factors included lack of sufficient evidence for optimal dosing and treatment 
duration for children and the paucibacillary nature of the MDR-TB in children, which 
may result in a faster clearance of the bacteria than in adults (see Ettehad, Schaaf, 
Seddon, Cooke, & Ford, 2012).  
Sampling and Sampling Procedures 
For the purpose of this research, I employed a convenience sampling approach. I 
collected secondary data from patients from states across Nigeria. I then extracted the 
data serially until I reached an adequate number that met the sample size requirement 
calculated for the study. The sampling frame included all MDR-TB patients managed in 
Nigeria between 2013 and 2014 who were older than 6 years and who were treated using 
either the hospital-based model or the community-based model. I excluded patients who 
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were enrolled in treatment after 2014 from the study. I also excluded patients whose 
treatment outcomes were not known at the time the study was being conducted. The 
secondary data I used for this study represented the routinely collected patient-level data 
of MDR-TB patients managed in Nigeria in line with the National TB treatment 
guidelines, which align with WHO guidelines for management of MDR-TB (see Falzon 
et al., 2011). I entered data routinely in both hard and electronic form for all patients 
enrolled in treatment. For the purpose of this study, I accessed the electronic data through 
the e-TB manager. I contacted the National Tuberculosis and Leprosy Control unit, which 
is part of the department of Public Health under the Ministry of Health, for permission to 
access the secondary data. I shared letters and held meetings to discuss the objective of 
the study. The Head of the Monitoring and Evaluation of the unit agreed to allow me to 
use the data by signing an agreement form.  
Sample Size Calculation 
In this study, I sought to determine the empirical relationship between five 
independent variables and two dependent variables. The independent variables were 
model of care whether hospital-based or community-based, existence of co-morbidities, 
specifically, HIV and gender, age, and as marital status. The dependent variables were 
treatment and survival outcomes, which I dichotomously classified for the purpose of this 
study. I classified the treatment outcome broadly into two categories of successful or 
unsuccessful outcomes, while I classified survival outcome as dead or alive. I applied 
logistics regression as the statistical analysis to determine the predictive relationship 
between the independent variables and the dependent variables. Using G*Power 3.1.9.2, I 
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calculated sufficient sample size for the study with an alpha of 0.05, power of 0.8, and a 
moderate effect size (odd ratio = 1.43) using a two-tailed test (Erdfelder, FAul, Buchner, 
& Lang, 2009). The effect size was based on a similar study conducted in South Africa to 
compare the effect of model of care on treatment outcomes (see Loveday et al., 2015).  
In this study, 1549 patients were prospectively enrolled on either community or 
hospital-based MDR-TB care. The settings of the study may not be exactly similar to the 
Nigerian context; however, the study design was robust and the sample size adequate to 
suggest a reliable result. The required sample size computed for determining the 
empirical validity for logistics regression with more than four predictor variables is a 
minimum of 392 patients.  
The power level, alpha, and effect size I chose for this study are the minimum 
required to determine the predictive relationship between the independent variables and 
the dichotomous dependent variable and it is consistent with the sample size applied in 
reliable literatures (e.g., Erdfelder et al., 2009; Ho et al., 2017).  
Instrumentation and Operationalization of Constructs 
 
I used secondary data for this study. I originally collected the data using routine 
data collection tools. I employed no instrument during the data collection process; 
therefore, review of reliability and validity of instrumentation was not necessary.  
Operationalization 
Treatment outcome is the dependent variable for this study. According to WHO 
definitions, treatment outcomes include cure, treatment completed, died, transferred out, 
loss to follow (WHO, 2014). Cure is defined as treatment completed as recommended by 
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the national policy without evidence of failure and three or more consecutive cultures 
taken at least 30 days apart are negative after the intensive phase (WHO, 2014a). 
Completed describes completion of the treatment course without bacteriologic 
documentation of cure. Failure is defined as treatment terminated or need for permanent 
regimen change of at least two anti-TB drugs because of lack of conversion by the end of 
the intensive phase or bacteriological reversion in the continuation phase after conversion 
to negative, or evidence of additional acquired resistance to fluoroquinolones or second-
line injectable drugs, or adverse drug reactions (ADRs) (WHO, 2014a). Transferred out 
describes patients transferred out of the country. Death is defined as death from any cause 
(TB or non-TB) during the course of chemotherapy (WHO, 2014a). Loss to follow up is 
used to describe any patient who had interrupted treatment of two consecutive months or 
more and who never returned for treatment. For the purpose of this study, treatment 
outcome will be classified into two broad categories, successful and unsuccessful. Cured 
and treatment completed will be considered as successful outcomes while other outcomes 
will be considered as unsuccessful, including loss to follow up, death and treatment 
failure. Transferred out patients will not be considered in the analysis.  
The key independent variable for this study was model of care. There are two 
categories, ambulatory or hospital-based model and the complete community or home-
based model of care. The ambulatory model is defined by WHO as models that involve 
in-patient management in the hospital under the close supervision of health workers for 
the duration of the intensive phase of about 6 months while complete community or 
home-based model of care involves management of the patients in their home or social 
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settings throughout the duration of treatment. This may involve visits to nearby health 
facilities for management of adverse reactions where necessary. Other dependent 
variables investigated in the study include the presence of co-morbidities or other 
diseases which in this study is defined as patients who are HIV positive in addition to 
having MDR-TB. This variable was treated as a dichotomous variable defined as co-
morbid or not co-morbid. Demographic characteristics such as gender, age and marital 
status were also investigated. Marital status was classified as single or married, age was 
classified as below and equal to 40 years and above 41 years of age in line with the 
findings from literature review (Li et al., 2016). Gender was classified as males and 
females.  
Data Analysis Plan 
I exported all data for the analysis into SPSS version 24 for Windows, which is 
the software I used for data analysis. I cleaned the data by ensuring that all necessary data 
elements were available. I attempted to retrieve all missing information; however, I did 
not include patients with missing or incorrect information on treatment outcome. I 
developed a data dictionary to define all the variables and how they were labelled or 
recoded for analysis. I recoded the data to prepare the data for analysis. I recoded age into 
age below or equal to 40 years and age above 41 years. I recoded marital status into 
single and married only; I recoded all divorced, separated, or widowed patients into the 
single category. I classified the outcome or dependent variable as successful and 
unsuccessful. I developed a data table to list all the dependent and independent variables 
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and their levels of measurement. For ease of interpretation of the results of the analysis, I 
recoded continuous variables such as age into categorical variables. 
Research Questions and Hypotheses 
RQ1: Is there an association between type of treatment model; hospital or 
complete community-based, and treatment outcome among MDR-TB patients in Nigeria? 
H01: There is no association between type of treatment model and treatment 
outcomes among MDR-TB patients in Nigeria. 
Ha1: There is an association between type of treatment model and treatment 
outcomes among MDR-TB patients in Nigeria. 
RQ2: Are co-morbidities such as HIV associated with poor treatment outcomes 
among MDR-TB patients in Nigeria? 
H02: There is no difference in treatment outcomes between patients with co-
morbidities and those without in Nigeria. 
Ha2: There is a difference in treatment outcomes between patients with co-
morbidities and those without in Nigeria. 
RQ3: Is type of treatment model associated with survival outcomes among MDR-
TB patients in Nigeria? 
H03: There is no difference in survival outcomes between patients enrolled on the 
two different models of care in Nigeria. 
Ha3: There is a difference in survival outcomes between patients enrolled on the 
two different models of care in Nigeria. 
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RQ4: Are demographic factors such as age, gender, and marital status associated 
with treatment outcomes among MDR-TB patients in Nigeria? 
H04: There is no association between demographic factors such as age, gender, 
marital status, and treatment outcomes among MDR-TB patients in Nigeria. 
Ha4: There is an association between demographic factors such as age, gender, 
marital status, and treatment outcomes among MDR-TB patients in Nigeria. 
I conducted descriptive analysis for each of the variables. These included 
frequencies, percentages, mean, mode, and median. I conducted the inferential analysis 
using logistics regression, using both bivariate and multivariate analysis to test each of 
the hypotheses. I determined the association between the dependent and each of the 
categorical independent variables using chi-square analysis. The level of significance was 
defined at 0.05 and the decision rule was to reject the null hypothesis if p was greater 
than 0.05. I calculated the odds ratio at each bivariate analysis using a confidence level of 
95%. The inferential statistics included hypothesis testing and the determination of the 
predictive relationship between the independent and dependent variables. If p-value was 
less than 0.05, I rejected the null hypothesis and confirmed the association between the 
predictive variables and the treatment outcomes among MDR-TB. I determined the effect 
size or the strength of the association using the value of the odds ratio. At the multivariate 
level of analysis, I included all the predictor variables in the model and used the adjusted 
odds ratio to determine which of the variables has the highest effect on treatment 
outcomes among MDR-TB patients. Potential confounders may be included in the 
analysis based on existing evidence in the literature. A key confounder that should have 
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been tested is the weight of the patient at the onset of treatment and type of smear at the 
beginning of treatment whether positive or negative (Kliiman & Altraja, 2009; Milanov 
et al., 2015). However, these variables were difficult to collect retrospectively. I tested 
conditions of linearity and multicollinearity to determine the appropriateness of the 
logistics regression as the method of analysis (see Field, 2009).  
Inferential Statistics 
I determined the overall significance of the logistic regression by examining the 
classification table, the display of the incorrect and correct classifications of the outcome 
variable. In addition, I used chi- square goodness of fit test to test the appropriateness of 
model. I used Wald statistic to determine the significance of each of the independent 
variables (Sperandei, 2014). Logistics regression analysis yields a model result that 
enables the prediction of the relationship between the dependent variable and the 
predictor variables by calculating the effect of each explanatory or dependent variables 
on the odds ratio of the observed event of interest which in this case is a successful 
treatment outcome and survival at end of treatment. The model summary provides the -2 
Log Likelihood statistic which measures how poorly the model predicts the decisions, a 
small statistic indicates a good model (Sperandei, 2014). I used the Snell R², Cox and 
Nagelkerke R² to determine the percentage of variance in the dependent variable that is 
explained by the predictor or independent variable (see Field, 2009). Also EXP (B) value 
shows the increase in odds from one unit increase in the selected variable (Field, 
2009).The omnibus result gives the outcome of the test of significance (Field, 2009). For 
the purpose of this study, p-value was set at 0.05. The decision rule was that the null 
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hypothesis is rejected, and the alternative accepted at p-values lower than 0.05. I set 
unsuccessful treatment outcome as the reference variable; hence, I interpreted results as 
the odds of having an unsuccessful treatment outcome as predicted by the explanatory or 
independent variable. 
Threats to Validity 
The sampling method did not include randomization, and this may have 
introduced selection bias as a result of the convenient sampling technique. This method 
may affect the internal validity of the results; however, I addressed this problem by 
ensuring that samples selected were diverse and came from different states in the country. 
External validity relates to the generalizability of the study findings to the general 
population (Creswell, 2012). I addressed issues relating to external validity by ensuring 
that the study was adequately powered and by limiting the interpretation of the findings 
of the study to the Nigerian setting. My use of secondary data for the analysis may 
introduce issues with the reliability of the data used because data quality cannot be 
improved at the point of use. I have stated these limitations in the study. Construct 
validity describes the appropriateness of the theoretical framework to the nature of the 
study (Creswell, 2012). I addressed construct validity by ensuring that the key constructs 
of the behavioral theory applied in this study were well aligned to each of the hypotheses 
tested in the study. I employed no instrument for data collection in this study because I 
used secondary data; therefore, measurement errors due to instrumentation are not 
applicable and did not affect the validity and reliability of the results. 
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Ethical Procedures 
I obtained permission to use secondary data from the institution responsible for 
management of tuberculosis patients, which is the National Tuberculosis, Buruli Ulcer 
and Leprosy Control Program. This permission took the form of a data agreement form 
that enabled unlimited access to the database of patient-level information of MDR-TB 
patients in the country. I anonymized and de-identified all patient information to ensure 
confidentiality. I managed the data with utmost discretion and stored them securely in 
electronic format using password protected laptops. Data dissemination also ensured that 
patient-level information was de-identified in order to ensure patient confidentiality. I 
met other IRB requirements of Walden University appropriately. 
Summary 
 
In this section, I described the research design and methodology I employed in the 
study. I applied a quantitative method. The population of interest were MDR-TB patients 
treated in Nigeria between 2013 and 2014. The study design was cross-sectional in 
nature. The patient-level data I used was, however, the retrospective cohort information 
of the patients that have concluded MDR-TB treatment. The predictor variables I 
investigated included model of care, existence of co-morbidities, gender, age, and marital 
status, while the dependent variable was treatment and survival outcomes, which are 
dichotomous in nature. I applied SPSS version 24 statistical software and used logistics 
regression as the method of analysis. Analysis included both descriptive and inferential 
analysis and I did inferential statistics at the bivariate and multivariate levels. The power 
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level was 80% and the p-value was set at 0.05 at 95% confidence level. In the next 
section, I will describe the results of the data analysis. 
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Section 3: Presentation of the Results and Findings 
Introduction 
The purpose of this study was to investigate the effect of model of care whether 
hospital-based, ambulatory or complete community-based model on the treatment 
outcomes of MDR-TB patients. I also investigated the effect of other factors such as the 
existence of other diseases such as HIV and demographic factors such as gender, age, and 
marital status on treatment outcomes of MDR-TB patients. The burden of MDR-TB in 
Nigeria makes it an important public health issue that has a heavy impact on the quality 
of life of those affected by the disease (Daniel & Osman, 2011). In light of this fact, the 
National TB program has adopted the complete community-based management of MDR-
TB alongside the ambulatory model of care to increase the treatment capacity to manage 
MDR-TB patients.  
The treatment of MDR-TB is extensive, toxic, and expensive both to the 
healthcare system and to the individual; hence, the need for a systematic evaluation of the 
effectiveness of existing models of care and some other key variables, such as the 
presence of comorbidities that may affect the outcome of the treatment. A patient-
centered approach to TB management is essential for achieving a positive outcome. Itis 
critical that policies and treatment guidelines adopted by the National TB programs are 
tested empirically to establish their effectiveness and appropriateness in the country’s 
context. A robust understanding of the factors that influence treatment outcomes among 
MDR-TB patients may be key in reducing the burden and impact of the disease. The 
result of this study may provide insights on how treatment outcomes among MDR-TB 
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patients can be improved by addressing some of the identified risk factors that are 
associated with poor treatment outcomes (see Drobniewski et al., 2002). Most 
importantly, the result of this study provided the evidence needed to inform policy 
changes in the management of MDR-TB patients in Nigeria particularly with regards to 
the model of care that is adopted and how care is delivered in general. Additionally, the 
findings of the study addressed the existing gap in literature as it relates to the 
demonstration of the effective model of care that is feasible for managing MDR-TB 
patients in resource-limited settings like Nigeria.  
Research Questions and Hypotheses 
RQ1: Is there an association between type of treatment model; hospital or 
complete community-based, and treatment outcome among MDR-TB patients in Nigeria? 
H01: There is no association between type of treatment model and treatment 
outcomes among MDR-TB patients in Nigeria. 
Ha1: There is an association between type of treatment model and treatment 
outcomes among MDR-TB patients in Nigeria. 
RQ2: Are co-morbidities such as HIV associated with poor treatment outcomes 
among MDR-TB patients in Nigeria? 
H02: There is no difference in treatment outcomes between patients with co-
morbidities and those without in Nigeria. 
Ha2: There is a difference in treatment outcomes between patients with co-
morbidities and those without in Nigeria. 
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RQ3: Is type of treatment model associated with survival outcomes among MDR-
TB patients in Nigeria? 
H03: There is no difference in survival outcomes between patients enrolled on the 
two different models of care in Nigeria. 
Ha3: There is a difference in survival outcomes between patients enrolled on the 
two different models of care in Nigeria. 
RQ4: Are demographic factors such as age, gender, and marital status associated 
with treatment outcomes among MDR-TB patients in Nigeria? 
H04: There is no association between demographic factors such as age, gender, 
marital status, and treatment outcomes among MDR-TB patients in Nigeria. 
Ha4: There is an association between demographic factors such as age, gender, 
marital status, and treatment outcomes among MDR-TB patients in Nigeria. 
Section 3 is divided into three subsections. The introduction contains a brief 
summary of research purpose, questions, and hypotheses. The result section includes a 
detailed explanation of the outcomes of both the descriptive and inferential statistical 
analysis. The results are organized by the research questions and hypothesis. Figures and 
tables are also included in the result subsection. 
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Data Collection of Secondary Data Set 
The data of MDR-TB patients are collected routinely at the facility and LGA 
level. Trained health workers who act as LGA tuberculosis and leprosy supervisors are 
responsible for the collation and reporting of TB and MDR-TB data for their respective 
LGAs. At the facility, there are trained health workers who are responsible for the 
primary collection of the patient level data using treatment cards and treatment registers. 
They are referred to as DOTS providers. Each of the states also have personnel 
designated as MDR-TB focal persons who are responsible for the coordination of the 
management of all MDR-TB patients in the state under the leadership of the state 
tuberculosis and leprosy program control manager. The data flow is such that the DOTS 
providers collect the patient level information which is collated by the LGA TB 
supervisor. Most states have a monthly meeting where the MDR-TB data are reviewed 
for accuracy and completeness. The MDR-TB data are entered into the electronic 
platform which is the e-TB manager by the MDR-TB focal person for the state. There are 
currently 28 treatment centers for MDR-TB in the country; these are facilities for the 
centralized management of MDR-TB patients and usually have patients transferred in 
from other states. For such facilities and because of the huge number of patients managed 
at that level, the patient level information is collated by a designated data officer and 
entered directly into the e-TB manager. The National Tuberculosis, Leprosy and Buruli 
Ulcer Control Program have a mechanism for data review and validation. This includes 
regular onsite data verification to facilities and LGAs, data quality assessments and a 
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quarterly data review meeting at the state level and for the six geopolitical zones in the 
country.  
Results 
 The final study included 402 patients selected from the population of MDR-TB 
patients managed in the country between 2013 and 2014. Of these patients, 137 (34%) are 
females and 262 (66%) are males. The gender of three of the patients included in the 
study could not be retrieved. There were more males in the sample than females in the 
study sample. This is consistent with the pattern of the gender distribution of TB patients 
in accordance with the findings of the prevalence survey conducted in the country in 
2012 and routine program data (National Tuberculosis and Leprosy Control Program, 
2012). The mean age of study participants was 33.98 years (standard deviation of 
11.634). Of the 402 patients, five (1.3%) were aged 7–14 years, 76 (19.5%) were aged 
15–24 years, 143 (36.7%) were aged 25–34 years, 95 (24.4%) were aged 35–44 years, 46 
(11.8%) were aged 45–54 years, 18 (4.6%) were aged 55–64 years and seven (1.8%) 
were aged 65 years and over. Of the patients whose information about age was included 
in the analysis, 297 (76.2%) of them were aged 40 years and below while 93 (23.8%) of 
them were aged 41 and above. The age of 12 of the patients included in the study could 
not be retrieved. Of the 402 patients included in the study, 213 (56.5%) were married, 
154 (40.8%) were single, eight (2.1%) were widowed, one (0.3%) was divorced and one 
(0.3%) was cohabitating but not married. Table 1 summarizes the sociodemographic 
characteristics of the study sample. 
53 
 
 
Table 1 
 
Frequency Distribution of Demographic Characteristics of Study Sample 
 Count (N) Percentage 
Variable 
 
Age (years) 
 
7-14 
 
15-24 
 
25-34 
 
35-44 
 
45-54 
 
55-64 
 
65 & over 
 
Total 
 
Gender 
 
Male 
 
Female 
 
 
 
 
 
5 
 
76 
 
143 
 
95 
 
46 
 
18 
 
7 
 
390 
 
 
 
262 
 
137 
 
 
 
 
 
1.3% 
 
19.5% 
 
36.7% 
 
24.4% 
 
11.8% 
 
4.6% 
 
1.8% 
 
100% 
 
 
 
65.7% 
 
34.3% 
 
Total 399 100 
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Table 1 (cont.) 
 
Frequency Distribution of Demographic Characteristics of Study Sample 
  
 Count (N) Percentage 
Variable 
 
Marital Status 
 
  
Married 
 
Single 
 
Widowed 
 
Divorced 
 
Cohabitating 
 
213 
 
154 
 
8 
 
1 
 
1 
56.5% 
 
40.8% 
 
2.1% 
 
0.3% 
 
0.3% 
Total 377 100 
 
 
 The age distribution of the study population reflects the distribution in the general 
population as described by the prevalence survey conducted in 2012. The age groups 25–
44 have the highest frequencies, as shown in Figure 2, thereby supporting the findings of 
the survey that the working age groups are the hardest hit by TB. This also partially 
explains the age cut-off point of 40 years that was used in the logistics regression 
analysis. Additionally, I applied this cut-off because it provided a midpoint between the 
study population mean age of 34 years and the cut-off point of 45 years as seen in the 
literature review. 
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Figure 2. Distribution of study population by age-groups. 
Patient Distribution by Model of Care 
Of the 402 MDR-TB patients included in the study, 188 were managed in the 
community and 214 were managed using the hospital-based or ambulatory model of care 
as shown in Figure 3. 
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Figure 3. Distribution of model of care. 
Distribution of Co-morbidities among Sample Population 
The sample population included 402 MDR-TB patients. Of the 402 patients, 356 
were HIV negative, 42 were HIV positive and the HIV status of four of the patients were 
unknown. It was difficult to retrieve information of other comorbidities that affected the 
patients particularly diabetes. Table 2 shows the distribution of co-morbidities among the 
sample population. 
Table 2 
 
Presence of Co-morbidities 
 Count (N) Percent Valid Cumulative 
Percent 
HIV Negative 
 
356 89.4% 89.4% 
HIV Positive 
 
Missing 
 
Total 
42 
 
4 
 
402 
10.6% 
 
1 
 
100 
 
100 
46.77%
53.23%
Treatment Model 
(Hospital-Based or Community)
Community Hospital
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Treatment Outcome Reported for Sample Population 
Of the 402 MDR-TB patients who were included in the analysis, 176 (43.8%) 
completed treatment, 149 (37.1%) were cured, 47 (11.7%) died, 2 (0.5%) failed treatment 
and 28 (7%) were lost to follow up. The treatment outcome was recoded into successful 
and unsuccessful outcomes with all cured and completed classified as successful 
outcomes and all other categories categorized as unsuccessful treatment. After recoding, 
325 (80.8%) of the MDR-TB patients had successful treatment outcomes while 77 
(19.2%) had unsuccessful treatment outcomes. 
Adherence to treatment was investigated by reviewing the number of patients who 
were lost to follow up in terms of their age category, gender, marital status and the model 
of care they were enrolled in before they defaulted. Of the 28 MDR-TB patients who 
were lost to follow up, 17 (60.7%) were enrolled for care in the community while 11 
(39.3%) were managed in the hospital before they defaulted. Based on gender 
distribution, 6.6% (9) of the female MDR-TB patients and 7.3% (19) of the male MDR-
TB patients were lost to follow up respectively. Based on marital, 14 of the patients were 
married while 11 of them were single, the marital status of the three of those lost to 
follow up was unknown. Based on age distribution, the age group with the highest 
proportion (14.3%) of patients who were lost to follow up were 65 years and above. This 
was followed by patients aged 55 years and above and then by patients between the ages 
of 45 to 54 years. None of the persons aged between 7 to 14 years were lost to follow up. 
Table 3 gives a summary of the distribution of the patients who were lost to follow up by 
age, gender, marital status, presence of HIV as a comorbidity and model of care. 
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Table 3 
 
Distribution of Patients Lost to Follow Up 
 
 
Loss to follow up N % (Number lost to follow 
up/N*100) 
Variable 
 
Age (years) 
 
7-14 
 
15-24 
 
25-34 
 
35-44 
 
45-54 
 
55-64 
 
65 & over 
 
Total 
 
Gender 
 
Male 
 
Female 
 
 
 
 
 
0 
 
4 
 
6 
 
4 
 
4 
 
2 
 
1 
 
28 
 
 
 
19 
 
9 
 
 
 
 
 
5 
 
76 
 
143 
 
95 
 
46 
 
18 
 
7 
 
 
 
 
 
262 
 
137 
 
 
 
 
 
0 
 
5.3 
 
7.7 
 
6.3 
 
8.7 
 
11.1 
 
14.3 
 
 
 
 
 
7.3 
 
6.6 
 
Total 28   
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Table 3 (cont.) 
 
Distribution of Patients Lost to Follow Up 
 
 
 
Loss to follow 
up 
N % (Number lost to 
follow up/N*100) 
Variable 
 
Marital Status 
 
Married 
 
Single 
 
 
 
 
 
14 
 
11 
 
 
 
 
 
214 
 
163 
 
 
 
 
6.5 
 
6.7 
 
Total 
 
 
Model of Care 
 
Community 
 
Hospital 
25 
 
 
 
 
17 
 
11 
 
 
 
 
 
188 
 
214 
 
 
 
 
 
9 
 
5.1 
 
Total 
 
 
Co-morbid HIV 
 
HIV Negative 
 
HIV Positive 
 
Total 
 
28 
 
 
 
 
23 
 
5 
 
28 
 
 
 
 
 
 
356 
 
42 
 
 
 
 
 
6.5 
 
11.9 
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Bivariate Analysis  
Research Question 1 
The first research question for this study was as follows: Is there an association 
between type of treatment model; ambulatory or complete community-based, and 
treatment outcome among MDR-TB patients in Nigeria? The null hypothesis was that 
there is no association between type of treatment model and treatment outcomes among 
MDR-TB patients in Nigeria. The alternate hypothesis was that there is an association 
between type of treatment model and treatment outcomes among MDR-TB patients in 
Nigeria. I tested the association between model of care and treatment outcome using chi-
square analysis. I classified model of care into two categories, namely hospital and 
community-based models of care. I broadly classified treatment outcomes into successful 
and unsuccessful outcomes. Successful outcomes included patients that completed 
treatment and those that were cured while unsuccessful treatment outcomes included 
those whose treatment failed, those who died, and patients that were lost to follow up and 
therefore did not complete the treatment. Both variables are categorical and independent 
of each other hence the conditions for using chi-square analysis were met. The outcome 
of the analysis showed a Pearson chi-square statistics test value of 1.607 and a p-value of 
0.205. The outcome of the analysis showed that out of the 188 (46.77%) patients who 
were managed in the community, 147 (78.2%) had a successful treatment outcome while 
41 (21.8%) had an unsuccessful treatment outcome. Out of the 214 (53.23%) patients 
who were managed in the hospital using the ambulatory approach, 178 (83.2%) had a 
successful treatment outcome while 36 (16.8%) had an unsuccessful treatment outcome. 
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The p-value of 0.205 is higher than 0.05 hence the null hypothesis was not rejected. This 
result indicates there is no sufficient evidence to establish that there is a difference in 
treatment outcomes between patients who were treated using the hospital-based model of 
care and those treated in the community. The odds of having a successful treatment when 
enrolled in the community model of care relative to the hospital-based model is 0.725, 
approx. 1. This value further supports the result of the hypothesis test that indicates 
inadequate evidence to reject the null hypothesis that there is no difference between the 
two models of care with regards to treatment outcomes. Table 4 shows the result of the 
cross tabulation for model of care and treatment outcome. 
Table 4 
 
Association between Model of Care and Treatment Outcome 
 
Treatment model Treatment outcome 
 
Total 
 Successful      
N (%) 
Unsuccessful    
N (%) 
 
Community 147 (78.2%) 41 (21.8%) 188  
Hospital 178 (83.2%) 36 (16.8%) 214  
Total 325 77 402 
p=0.205 
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Research Question 2 
The second research question was as follows: Are co-morbidities such as HIV 
associated with poor treatment outcomes among MDR-TB patients in Nigeria? The null 
hypothesis stated that there is no difference in treatment outcomes between MDR-TB 
patients who have HIV as a co-morbid condition and those who do not. The alternate 
hypothesis stated that there is a difference in the two groups. I coded the independent 
variable into presence of HIV as a co-morbid condition, yes or no. Both variables are 
categorical and independent of each other hence the conditions for using chi-square 
analysis were met. The outcome of the analysis showed a Pearson chi-square statistics 
test value of 1.657 and a p-value of 0.198. The outcome of the cross-tabulation showed 
that out of the 356 (89.4%) patients who were HIV negative, 292 (82%) had a successful 
treatment outcome while 64 (18%) had an unsuccessful treatment outcome. Out of the 42 
(10.6%) patients who were HIV positive, 31 (73.8%) had a successful treatment outcome 
while 11 (26.2%) had an unsuccessful treatment outcome. The p-value of 0.198 is higher 
than 0.05 hence the null hypothesis was not rejected. This result indicated that there is no 
sufficient evidence to establish that there is a difference in treatment outcomes between 
patients who were HIV positive and those without HIV comorbidity. The odds of having 
a successful treatment when HIV negative relative to having HIV as a comorbidity is 
1.619. This shows a slightly higher odd of having a successful treatment outcome for 
HIV negative patients, but the difference observed is not statistically significant. Table 5 
shows the result of cross-tabulation of treatment outcome and HIV status. 
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Table 5 
 
Association between Co-morbidities and Treatment Outcome 
Treatment outcome Presence of co-morbidities Total 
 
 HIV negative   
N (%) 
HIV positive     
N (%) 
 
Successful 292 (82%) 31 (73.8%) 323 
 
 
Unsuccessful 64 (18%) 11 (26.2%) 75 
 
 
Total 356 42 398 
 
P = 0.198  
   
Research Question 3 
The third research question was as follows: Is type of treatment model associated 
with poor survival outcomes among MDR-TB patients in Nigeria? The null hypothesis 
was that there is no difference in survival outcome among patients enrolled in the two 
model of MDR-TB care in Nigeria. The alternate hypothesis was that there is a difference 
in survival outcomes among patients enrolled in either community or hospital-based 
model of care. The dependent variable is survival outcome, which I defined as dead or 
alive at the end of the MDR-TB treatment regimen. I classified patients who died from 
any cause during the course of the treatment as dead and those who were alive at the end 
of the treatment period as alive. I classified the survival outcome into two categories of 
dead or alive. The outcome of the analysis showed a Pearson chi-square statistics test 
value of 0.208 and a p-value of 0.649. The outcome of the cross-tabulation showed that 
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out of the 188 (46.77%) patients who were enrolled under the community model of care, 
166 (88.3%) survived while 22 (11.7%) died before the end of the treatment period. Out 
of the 214 (53.23%) patients who were enrolled under the hospital-based model of care, 
192 (89.7%) survived, while 22 (10.3%) died before the end of the treatment period. The 
p-value of 0.649 is higher than 0.05 hence the null hypothesis was not rejected. This 
result indicated that there is no sufficient evidence to establish that there is a difference in 
survival outcomes between patients who were enrolled on the hospital-based model of 
care and those managed in the community. The odds of surviving the MDR-TB treatment 
regimen when enrolled in the community relative to the hospital model of care were 
0.865, approx. 1. This underscores the result of the hypothesis testing which indicates 
insufficient evidence to reject the null hypothesis that there is no difference in survival 
outcomes between patients enrolled in the two models of care. Table 6 shows the result of 
cross-tabulation of model of care and survival outcomes. 
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Table 6 
 
Association between Treatment Outcome Model and Survival Outcome 
Survival outcome Treatment model Total 
 
 Community    
N (%) 
Hospital            
N (%) 
 
Alive 166 (88.3%) 192 (89.7%) 358 
 
 
Dead 22 (11.7%) 22 (10.3%) 44 
 
 
Total 188 214 402 
 
p=0.649 
 
Research Question 4 
The fourth research question was as follows: Are demographic factors such as 
age, gender and marital status associated with poor treatment outcomes among MDR-TB 
patients in Nigeria? The null hypothesis was that there is no association between 
demographic factors such as age, gender, marital status and poor treatment outcomes 
among MDR-TB patients in Nigeria while the alternate hypothesis was that there is an 
association between demographic factors such as age, gender, marital status and poor 
treatment outcomes among MDR-TB patients in Nigeria. I analyzed age in its natural 
state as a continuous variable using logistics regression and I also recoded it into a 
categorical variable with the two categories, age equals or is less than 40 years and age is 
greater than 41 years. I recoded marital status into single and married; I recoded all those 
who were divorced, widowed, or separated as single and those who were married or 
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cohabitating as married. I recoded with the objective of capturing the essence of having a 
partner living in the household as the patient. I classified gender as males and females. I 
applied chi square analysis to determine the association between age and treatment 
outcome, marital status and treatment outcome, and gender and treatment outcome. 
Age and Treatment Outcome 
 The result of the logistics regression analysis showed an odds ratio of 1.027 (95% 
C1: 1.006-1.049) at a p-value of 0.013 This p-value is less than 0.05 therefore the null 
hypothesis was rejected. Age is therefore a good predictor of the outcome of MDR-TB 
treatment. The older the MDR-TB patient, the higher the chances of having an 
unsuccessful treatment outcome and for every one-unit increase in age, the odds of 
having an unsuccessful treatment outcome increases by about 3%. The outcome of the 
chi-square analysis for the recoded age variable showed a Pearson chi-square statistics 
test value of 4.967 and a p-value of 0.026. The outcome of the cross-tabulation showed 
that out of the 297 (76.2%) patients who were aged 40 years and below, 248 (83.5%) had 
a successful treatment outcome while 49 (16.5%) had unsuccessful treatment outcome. 
Out of the 93 (23.8%) patients who were aged 41 years and above, 68 (73.1%) had 
successful treatment outcome while 25 (26.9%) had unsuccessful treatment outcome. The 
p-value of 0.026 is lower than 0.05 hence the null hypothesis was rejected. This result 
indicates that there is an association between age and treatment outcomes among MDR-
TB patients. The odds of having a successful treatment when aged 40 years and lower 
relative to age 41 years and above is 1.861. This shows higher odds of having a 
successful treatment outcome for the younger age group, about 86% more than the 
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patients aged 41 years and above. The observed difference is statistically significant, and 
it is in consonance with the result of the logistics regression analysis. Table 7 shows the 
result of cross-tabulation of age and treatment outcomes. 
Table 7 
 
Association between Age and Treatment Outcome 
 
Treatment outcome Age Total 
        
 1-40yrs          
N (%) 
>=41yr              
N (%) 
 
Successful 248 (83.5%) 68 (73.1%) 316 
 
 
Unsuccessful 49 (16.5%) 25 (26.9%) 44 
 
 
Total 297 93 390 
p=0.026  
 
Gender and Treatment Outcome 
The outcome of the chi-square analysis showed a Pearson chi-square statistics test 
value of 0.186 and a p-value of 0.666. The outcome of the cross-tabulation showed that 
out of the 262 (65.7%) patients who are male, 215 (82.1%) had a successful treatment 
outcome while 47 (17.9%) had unsuccessful treatment outcome. Out of the 137 (34.3%) 
patients who are female, 110 (80.3%) had successful treatment outcome while 27 
(19.7%) had unsuccessful treatment outcome. The p-value of 0.186 is higher than 0.05 
hence the null hypothesis was not rejected. This result indicates that there is no sufficient 
evidence to establish that there is an association between gender and treatment outcomes 
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among MDR-TB patients. The odds of having a successful treatment when male relative 
to female is 1.123. This shows a slightly higher odd of having a successful treatment 
outcome for males, however, the observed difference is not statistically significant. Table 
8 shows the result of cross-tabulation of gender and treatment outcomes. 
Table 8 
Association between Gender and Treatment Outcome 
Treatment outcome Gender Total 
 Female            
N (%) 
Male              
N (%) 
 
Successful 110 (80.3%) 215 (82.1%) 325 
 
Unsuccessful 27 (19.7%) 47 (17.9%) 74 
 
Total 137 262 399 
p = 0.186, N=399  
Marital Status and Treatment Outcome 
 The outcome of the chi-square analysis showed a Pearson chi-square statistics test 
value of 0.000 and a p-value of 0.993. The outcome of the cross-tabulation showed that 
out of the 214 (56.8%) patients who are married, 176 (82.2%) had a successful treatment 
outcome while 38 (17.8%) had unsuccessful treatment outcome. Out of the 163 (43.2%) 
patients who were single, 134 (82.2%) had successful treatment outcome while 29 
(17.8%) had unsuccessful treatment outcome. The p-value of 0.993 is higher than 0.05, 
hence the null hypothesis was not rejected. This result indicates that there is no sufficient 
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evidence to establish that there is an association between marital status and treatment 
outcomes among MDR-TB patients. The odds of having a successful treatment when 
married relative to being single is 1.002. This shows similar odds of having a successful 
treatment outcome for the married and single patients. Similarly, when gender was 
adjusted by marital status, the odds of having an unsuccessful treatment outcome was 
similar for both single males and females with an odds ratio of 1.074 at a p-value of 0.8 
which shows no statistical significance. Table 9 shows the result of cross-tabulation of 
marital status and treatment outcomes. 
Table 9 
 
Association between Marital Status and Treatment Outcome 
 
Treatment outcome Marital status Total 
 
 Married 
N (%) 
Single                 
N (%) 
 
Successful 176 (82.2%) 134 (82.2%) 310 
 
 
Unsuccessful 38 (17.8%) 29 (17.8%) 67 
 
 
Total 214 163 377 
 
P=0.993 Note: N=377 
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Multivariate Analysis  
 I included all the independent variables tested at the bivariate level in a logistics 
regression model to determine the association between them and the dependent variable, 
which is treatment outcome. I determined the significance of the logistic regression 
model by reviewing the classification table, which displayed the percentage accuracy of 
the model. In addition, I used the Hosmer Lemeshow goodness of fit test to test the 
appropriateness of model. Both tests showed a fairly accurate model with a classification 
value of 81.9% and a Wald statistics value of 125.945 for the fully adjusted model that 
included all the independent variables. The independent variables included in the model 
were model of care, gender, marital status, age, and presence of HIV as a co-morbidity. 
The outcome of the logistics regression analysis showed that model of care and age were 
predictors of treatment outcomes. At the bivariate analysis, the association between 
model of care and treatment outcome was not statistically significant; however, after 
adjusting for age, gender, marital status, and the presence of HIV as a co-morbidity, 
model of care was found to be a predictor of treatment outcome. The result of the 
logistics regression showed that an odds ratio of 1.737 (95% C1: 1.004, 3.007) for 
patients enrolled in community having an unsuccessful treatment outcome relative to the 
patients managed in the hospital at a p-value of 0.048. This p-value is less than 0.05, 
hence the observed difference is not likely to be due to chance. This result suggests that 
patients managed in the community are 74% more likely to have an unsuccessful 
treatment than patients managed in the hospitals. For age, the result of the analysis 
showed an odds ratio of 1.948 (95% C1: 1.021, 3.716) for patients aged 41 years and 
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above to have an unsuccessful treatment outcome relative to the younger age category of 
40 years and younger, at a p-value of 0.043. This result shows that patients 41years and 
above are 95% more likely to have an unsuccessful treatment outcome relative to patients 
aged 40 years and below. Marital status, gender, and presence of co-morbidity, 
specifically HIV, were not significantly associated with treatment outcome. Similarly, 
gender adjusted by marital status was not significantly associated with treatment 
outcome. Therefore, based on the findings of this study, married males were just as likely 
to have successful treatment outcomes for MDR-TB as their single counterparts and the 
same applied for the females. Table 10 shows the summary result of the fully adjusted 
logistics regression model.  
Table 10 
 
Result of Multivariate Binary Logistics Regression Analysis 
 
Model of care and age were predictors of treatment outcome with p-values less than 0.05. 
Reference categories are hospital model of care, age=/>40 years, male, single and 
HIV+. 
Description B S.E. Wald      df Sig.  aOR   95% C.I. for OR 
Lower Upper 
Age .667 .330 4.089 1 .043 1.948 1.021 3.716 
Marital status -.201 .302 .444 1 .505 .818 .452 1.478 
 Gender .139 .292 .228 1 .633 1.149 .649 2.035 
Presence of 
comorbidities 
(HIV) 
-.158 .496 .102 1 .750 .854 .323 2.255 
Treatment model  .552 .280 3.896 1 .048 1.737 1.004 3.007 
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Summary 
In this section, I presented the results of the analysis of the MDR-TB patient 
level data, which included age, gender, marital status, presence of HIV as comorbidity, 
and model of care whether community or hospital-based as independent or predictor 
variables. Treatment outcome and survival outcomes were the dependent variables. At 
the bivariate level, I found only age to be associated with treatment outcome while at the 
multivariate level, I found model of care to be a predictor of treatment outcome after 
adjusting for gender, age, marital status, and presence of HIV as a comorbidity. The 
analysis showed the importance of age when managing MDR-TB patients and suggests 
that patients enrolled in communities may have a higher likelihood of having 
unsuccessful treatment when older. 
In the next section of this dissertation, I will discuss the findings of my analysis 
with reference to similar published studies. I will apply the Health Belief Model to 
improve treatment adherence amongst MDR-TB patients. 
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Section 4: Application to Professional Practice and Implications for Social Change  
Introduction 
The burden of TB has become a public health issue in countries such as China, 
India, and Nigeria, among others (World Health Organization [WHO], 2016). The huge 
burden of TB in these countries has made it pertinent to increase their respective 
capacities to manage MDR-TB patients. Nigeria has grappled with one of the highest 
burdens of MDR-TB, which has had a negative impact on the quality of life of those 
affected by the disease (Daniel & Osman, 2011). In light of this fact, the National TB 
program has adopted a complete community-based management of MDR-TB alongside 
the ambulatory model of care to increase the treatment capacity to manage MDR-TB 
patients. In the face of this expansion of treatment capacities, there has been limited 
empirical evidence to establish the effectiveness of the community-based model of care 
for MDR-TB patients in Nigeria. This study sought to demonstrate the effect of the 
model of care and existence of co-morbidities such as HIV on treatment outcomes among 
MDR-TB patients.  
Summary of Findings 
A total of 402 MDR-TB patients were included in the analysis. There were 137 
(34.3%) females and 262 (65.7%) males. This shows a preponderance of males that is in 
consonance with the gender distribution reported in the national prevalence survey 
conducted in 2012 and routine programmatic data. The distribution of the patients in 
terms of treatment model was fairly equal with 184 (46.8%) enrolled on the community 
model of care and 214 (53.2%) managed in the hospitals. The age group of 25−44 years 
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accounted for 61% (238 out of 390) of the sample population with known age, this 
formed the majority followed by the age group 15−24 years which formed 19.5% of the 
sample population with known age. The least represented age groups are seven to 14 
years and 65 years and above which accounted for only 1.3% and 1.8% of the sample 
population respectively. The sample population also showed a fairly even distribution of 
marital status with 213 (56.5%) of the patients being married and 154 (40.8%) being 
single. Other categories for marital status include divorced patients (one, 0.3%), widowed 
(eight, 2.1%) and cohabitating but married (one, 0.3%). 356 (89.4%) of the patients were 
HIV negative while 42 (10.6%) were people living with HIV. The status of 4 of the 
patients was unknown. 
In this study, I focused on investigating the effect of model of care on treatment 
outcome among MDR-TB patients. I also reviewed other factors that may affect 
treatment outcome such as age, gender, marital status, and presence of HIV as a 
comorbidity. At the bivariate level, I did not find model of care to be a predictor of 
treatment outcome as the difference observed between the two models in terms of 
treatment outcomes were not statistically significant. I found age to be significantly 
associated with treatment outcome at a p-value of 0.026. Patients 40 years and younger 
were found to be 1.86 times more likely to have a successful treatment outcome 
compared with patients aged 41 years and above. Presence of HIV as a comorbidity as 
well as marital status and gender were not significantly associated with treatment 
outcome. The outcome of the survival outcome analysis showed that model of care was 
not significantly associated with survival outcome (p-value=0.865). At the multivariate 
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level, age and model of care were found to be significantly associated with treatment 
outcomes. Age at a p-value of 0.043, is a predictor of treatment outcome with patients 
aged 41 years and above having 1.948 more odds of having an unsuccessful treatment 
outcome relative to patients aged 40 years and below. Model of care is a predictor of 
treatment outcome with patients enrolled in the community being 1.737 times more likely 
to have an unsuccessful treatment outcome than patients managed using the hospital-
based approach (p-value of 0.048). 
In this study, I addressed four key research questions, which are as follows.  
RQ1: Is there an association between type of treatment model; hospital or 
complete community-based, and treatment outcome among MDR-TB patients in Nigeria? 
RQ2: Are co-morbidities such as HIV associated with poor treatment outcomes 
among MDR-TB patients in Nigeria? 
RQ3: Is type of treatment model associated with survival outcomes among MDR-
TB patients in Nigeria? 
RQ4: Are demographic factors such as age, gender, and marital status associated 
with treatment outcomes among MDR-TB patients in Nigeria? 
Interpretation of the Findings 
General Issues 
There were more MDR-TB patients aged 25−44 years (61%) in the study 
population. More males than females were affected by MDR-TB based on the sample 
population, 65.7% While females were only 34.3%. This gender distribution suggests a 
male preponderance in the burden of MDR-TB. The percentage of the MDR-TB patients 
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who were HIV positive was 10.6%. In Nigeria, the proportion of TB patients with HIV 
comorbidity is 19.1% (Adejumo, Daniel, Otesanya, Adegbola, & Femi, 2017). This 
statistic suggests that while the country may have achieved great strides in reducing the 
burden of TB/HIV co-infection, the National TB Program may be missing a lot of TB 
cases among people living with HIV (Adejumo et al., 2017). The low detection rate 
among this group may not be unrelated to the difficulties that abound with TB diagnosis 
in people living with HIV. This is due to their poor immune response to the presence of 
the mycobacterium tuberculosis which often makes it difficult to detect the organism in 
their sputum, hence many of them present as smear negative TB (Adejumo et al., 2017). 
There are newer and more sensitive diagnostics now such as the TB-LAM which can 
detect TB in urine samples of people living with HIV (WHO, 2015c). This development 
along with the policy to commence antiretroviral therapy in all TB HIV co-infected 
patients may address the difficulties in diagnosing TB among this key population 
(Ministry of Health Nigeria, 2010). 
The findings of this study suggest that MDR-TB patients with HIV co-morbidity 
were not particularly at risk of poorer treatment outcomes compared to their HIV 
negative counterparts. This can be explained by the fact that all MDR-TB patients with 
HIV co-morbidity are all placed on antiretroviral therapy in line with the national 
TB/HIV guidelines (Ministry of Health Nigeria, 2010). 
Treatment Model and Treatment Outcomes 
The result of the analysis investigating the relationship between model of care and 
treatment outcome showed that community model of care had a slightly higher proportion 
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of patients with unsuccessful treatment outcome (21.8%) compared to the hospital-based 
approach (16.8%). The result was however not statistically significant with a p-value of 
0.205. At the multivariate level, the result was statistically significant at a p-value of 
0.048 and an adjusted odds ratio of 1.737 (95% C1: 1.021, 3.716). This result suggests 
that the two models of care for managing MDR-TB patients in Nigeria, community and 
hospital may lead to similar treatment outcomes among MDR-TB patients. This is in 
agreement with Bassili et al. (2013)’s findings, which showed that community treatment 
model is an optimal model for treating MDR-TB patients. This finding also suggests that 
the National TB program in Nigeria has deployed the model effectively and addressed the 
challenges that are often associated with community model of care for MDR-TB. These 
challenges include difficulty in managing adverse drug reactions in the community and 
long distance to health facilities in case of complications, amongst others (Weiss et al., 
2014). 
Adjusting for age and marital status, the hospital model appeared to lead to higher 
rates of successful treatment outcomes than the community model. Higher proportion of 
the MDR-TB patients managed in the hospital (83.2%) had successful treatment outcome 
relative to the community model (78.2%). These similar treatment success rates among 
the two models of care corroborates the findings of Weiss et al. (2014) and Kalandrova et 
al. (2016) which indicated that community model of care for MDR-TB patients is 
comparable to the hospital-based model of care in terms of the treatment outcomes of the 
patients. Also, the Cox et al. (2014), Loveday et al. (2015), Williams et al. (2016), and 
Taneja (2017) found favorable treatment outcomes when MDR-TB patients were 
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managed in the community in countries like South Africa, Swaziland and China, among 
others.  
This is, however, contrary to the findings of Oladimeji et al. (2014), in which the 
authors suggested that patients managed in the hospital may have better treatment 
compliance as indicated by the zero loss to follow up reported by the study. The design of 
the study was descriptive and did not compare treatment compliance between patients 
enrolled in the hospitals versus those managed in the community. The similar treatment 
outcomes seen for the two models of care underscores the support systems built into the 
community MDR-TB management program which includes the use of treatment 
supporters and the extensive social and psychosocial support provided to the MDR-TB 
patients by family members and loved ones (USAID TB CARE II, 2017). Managing 
MDR-TB patients in their natural environment as against the confinement of the hospital 
environment may have contributed to improved treatment outcomes. This corroborates 
the findings of Bieh et al. (2017), who highlighted the psychological trauma and health 
provider-related discrimination suffered by MDR-TB patients when managed using the 
hospital-based model of care.  
Researchers have also found the community model of care to be more cost-
effective than the hospital approach and all of these advantages of the community 
approach combine to make it a more practical option for managing MDR-TB patients 
(Fitzpatrick & Floyd, 2012; Musa et al., 2016). Also, the Loveday et al. (2014) suggested 
that there is a relationship between health system performance and treatment outcomes of 
patients managed using the decentralized or community model of care. Health systems 
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performance in this context were measured using a combination of factors which include 
availability of motivated health staff, uninterrupted supply of medications, effective 
laboratory systems to support treatment monitoring, integration of MDR-TB, and HIV 
services, among others. The TB program in Nigeria is supported by the Global Fund, 
USAID, and other partners; therefore, in spite of the inadequacies of the health systems in 
general, measures have been put in place by the supporting agencies to address key gaps 
in the health systems (NTLP, 2013). These include provision of financial support to 
MDR-TB patients to cover nutritional needs and transportation costs to the hospitals 
where needed, technical support to ensure optimal functionality of the logistics and 
supply chain of anti-TB medications in the country and support for regular quality 
assurance reviews of the laboratory systems, among others. With these mechanisms in 
place, it is safe to state that the community model of care showed similar treatment 
outcomes to the hospital-based approach because it was implemented in the context of a 
relatively effective health performance system. 
Age and Treatment Outcomes 
 I found age to be significantly associated with treatment outcome. My analysis 
suggested that the older the patient, the more likely that patient was to have an 
unsuccessful treatment outcome. For every one unit of age, the likelihood of having an 
unsuccessful treatment outcome increased by 1.027. Based on the results, patients aged 
41 years and above have higher odds of having an unsuccessful treatment outcome. This 
result supports Wai et al.’s (2017) and Li et al.’s (2016) findings that older age ranging 
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45−55 years and above was a predictor of poor treatment outcomes among MDR-TB 
patients.  
This finding is incongruent with the finding of Skrahina et al. (2013), who found 
that younger age was associated with poor treatment outcome among MDR-TB patients 
at a p-value of 0.24. The result of this study is in line with existing evidence that old age 
is associated with poorer health outcomes (i.e. Deeks, Lombard, Michelmore, & Teede, 
2009). Older patients may have other health conditions that predispose to poor treatment 
outcomes when managed for MDR-TB. These comorbidities may also lead to drug-to-
drug interactions that may reduce the efficacy of the drugs used for managing MDR-TB. 
It was however not possible to investigate the effect of other comorbidities that may have 
resulted in poorer treatment outcomes among the older MDR-TB patients in this study.  
The finding that old age is a predictor of poor treatment outcome has significant 
implications for the design and implementation of MDR-TB program in Nigeria. It is 
particularly important when making decisions on the model of care patients with which to 
manage MDR-TB patients. Policies and guidelines that are tailored to account for the 
vulnerability of the older patients when undergoing MDR-TB treatment should be 
developed. Specific support and age-sensitive program designs need to be instituted as a 
deliberate response of the National TB Program to the needs of the older MDR-TB 
patients.  
Gender and Treatment Outcomes 
 I did not find any significant relationship between gender and treatment outcome. 
Male patients were just as likely to have successful treatment outcomes as their female 
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counterparts. This finding is similar to that of Patel et al. (2016), who found that there 
was no sufficient evidence to suggest an association between gender and treatment 
outcome. This is contrary to the finding of Skrahina et al. (2013), who found that the 
male gender was a predictor of poor treatment outcomes among MDR-TB patients at a p-
value of 0.001. 
The results of this study show a contrary finding to the general tendencies for men 
to have poorer health seeking behavior than women and for women to play the role of the 
healthcare gatekeepers in families (see Deeks et al., 2009; Ostlin, Eckermann, Mishra, 
Nkowane, & Wallstam, 2006). Also, there are biological differences between males and 
females that lead to differentials in health outcomes as measured using life expectancies, 
with women generally having longer life expectancies than their male counterparts 
(Vlassoff, 2007). Some have, however, argued that biological differences alone cannot 
account for the health disparities observed between males and females considering the 
fact that gender is constructed socially (Ostlin et al., 2006). Hence, social and economic 
factors also explain the gender-related difference observed in health (Ostlin et al., 2006). 
While many health interventions have been accused of being gender blind, it appears that 
there is no sufficient evidence for gender-related disparities in treatment outcomes among 
the MDR-TB patients I investigated in this study. The similarity in treatment outcomes 
observed between the male and female MDR-TB patients in this study may be due to 
confounding variables such as the quality of psychosocial support available to patients as 
well as the use of treatment supporters which in the case of males may be mostly females. 
Female treatment supporters may have assisted the male patients to comply to treatment 
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and this may have masked the poor health seeking behavior that is often associated with 
the male gender. It is, however, important to explore the possibilities of such gender-
related inequities in outcomes in future studies, with particular reference to treatment 
compliance.  
Marital Status and Treatment Outcomes 
The study results did not show any significant relationship between marital status 
and treatment outcome. Married patients were just as likely to have successful treatment 
outcomes as their unmarried counterparts. This was similar to Patel et al.’s (2016) 
findings that no statistically significant relationship between marital status and treatment 
outcomes existed among MDR-TB patients in India. While Lund (2006) suggested that 
living alone was associated with poorer health outcomes, the possibilities of other 
external factors such as social and economic factors confounding the observed 
association have not been fully explored. However, there are reasons to explain the better 
health outcomes in persons cohabitating with partners, including the emotional 
satisfaction of having someone to turn to in times of ill-health and psychosocial support 
provided by partners that may improve treatment compliance (Robards, Evandrou, 
Falkingham, & Vlachantoni, 2012). It is important to note that the quality of such living 
arrangements and relationships also matter in terms of the effect on health and in this 
case, treatment outcome of MDR-TB patients. Partners may not be supportive of 
treatment. In extreme cases, gender and domestic violence may even worsen treatment 
compliance thereby leading to poor treatment outcomes (Robards et al., 2012). In light of 
this fact, it is important to explore the impact of marital relationships and living 
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arrangements on treatment outcomes among MDR-TB patients while taking into account 
factors such as quality of relationship, economic situation, religion and the presence of 
other social networks and support systems. 
Presence of HIV as a Comorbid Condition and Treatment Outcomes 
The study findings did not show any significant relationship between HIV 
comorbidity and treatment outcome. People living with HIV patients were just as likely 
to have successful treatment outcomes as those HIV negative. These findings corroborate 
the findings of Satti et al. (2012) that effective management of HIV with the use of 
antiretroviral therapy (ART) resulted in similar treatment outcomes among co-infected 
and HIV negative patients. The result of this study is however contrary to the finding of 
Skrahina et al. (2013) that presence of HIV was a predictor of unsuccessful treatment 
outcomes. Aibana et al. (2017) and Kiliiman & Altraja (2009) similarly suggested that 
HIV comorbidity and not being on ART were associated with poor treatment outcomes 
among MDR-TB patients. The findings of this study suggest that the National TB 
program may not be doing so badly when it comes to managing TB/HIV co-infected 
patients and the adoption of the policy to place all TB/HIV co-infected patients on ART 
in 2010 may have impacted positively on the treatment outcomes among MDR-TB 
patients as suggested by the findings of this study (Ministry of Health Nigeria, 2010). 
Model of Care and Survival Outcomes 
The findings of the study show that model of care is not significantly associated 
with survival outcomes; therefore, patients enrolled in the community have an equal 
chance of surviving the MDR-TB treatment regimen as patients managed in the hospital. 
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This finding corroborates the findings of Heller et al. (2010), Ho et al. (2017), and Taneja 
(2017), all of whom indicated favorable survival outcomes among patients managed in 
the community. However, the results of this study are incongruent with the findings of 
Loveday et al. (2015), who found lower survival rates among patients managed in the 
community. The reasons for the observed similarity in survival outcomes are similar with 
those stated for model of care and treatment outcome. Effective decentralization of 
MDR-TB care using the community model of care appears to influence survival 
outcomes positively because patients are managed in their natural environment and have 
access to psychosocial support from family members and other social networks (Loveday 
et al., 2015). Also, as stated by Bieh et al. (2017), health worker-related discrimination of 
MDR-TB patients may be associated with poor treatment outcomes. This negative 
external factor is mitigated when patients are managed in the community and may be 
responsible for the optimal survival outcomes in the community. Reducing the indirect 
costs related to hospital admissions may reduce the catastrophic costs associated with 
MDR-TB treatment thereby leading to lower stress levels for the patients (Fitzpatrick & 
Floyd, 2012). Additionally, while patients confined in the hospitals may be expected to 
have lower rates of follow up compared to those managed in the community, it appears 
that the National TB program’s provision of psychosocial support, through treatment 
supporters, may have mitigated the risk of treatment default associated with community 
or home-based care in general. These treatment supporters are often family members or 
healthcare workers who are trained to support the patient psychologically throughout the 
treatment period. 
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Analysis and Interpretation of Findings in Context of HBM 
The HBM was originally developed to improve uptake of tuberculosis screening 
services, therefore it has the essential characteristics to address the issues related to social 
stigma and other factors that are barriers to the uptake of TB services. HBM is applicable 
for improving MDR-TB treatment outcomes particularly with regards to treatment 
adherence. The modifying factors of HBM in the context of MDR-TB management in 
this study include age, gender and marital status. These factors may have some level of 
influence on the way the patients perceive their susceptibility to an unsuccessful 
treatment outcome if treatment compliance is not achieved. Age greater than 40 years 
was found to be significantly associated with unsuccessful treatment outcome. It is 
however not clear from this study if the poorer treatment outcomes seen among patients 
older than 40 years is related to poor treatment adherence. Marital status was not 
associated with treatment outcomes, therefore single persons, the widowed and others 
who may not live with civil partners or “spouses” were not more likely to comply to 
MDR-TB treatment compared to their married counterparts. However, treatment 
adherence using loss to follow up as a proxy appears to be better among the married 
population. This may be explained by the fact that the presence of a significant other or a 
civil partner o may provide the psychosocial support needed by the patients to adhere to 
MDR-TB treatment especially if the partner is empowered to support treatment. Gender 
was also found not to be significantly associated with treatment outcomes, however there 
was a higher proportion of loss to follow up among males. This is in consonance with 
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existing evidence which suggests that males have poorer health seeking behavior which 
may also reflect in the way they comply to treatment regimens (Vlassoff, 2007).  
In addition, the findings of the study showed that 28 (7%) of the patients were lost 
to follow up with loss to follow up being used a proxy to describe treatment non-
compliance among the MDR-TB patients. Of these, the greater proportion were the 
patients in the community model of care relative to the hospital model. The highest rate 
of loss to follow up was seen amongst the patients aged 55 years and above and the 
lowest rate was seen among patients aged 7−14 years. Males were more likely to be lost 
to follow up than females. The proportion of patients that were lost to follow up was also 
different for the married patients, with married patients having a marginally lower 
proportion compared to the single patients. For HIV status, people living with HIV have 
higher proportion of loss to follow up compared to HIV negative patients. This result is 
similar to the finding of a study conducted in Nigeria which suggests that loss to follow 
up was associated with being HIV co-infected (Ifebunandu & Ukwaja, 2012). The 
explanation provided for this is the pill burden of taking ARVs as well as anti-TB 
medications, side effects from both medications as well as the need to access care for 
both diseases in different health facilities (Ifebunandu & Ukwaja, 2012). These are 
potential barriers to treatment adherence for MDR-TB patients with HIV as a co-
morbidity. A similar study stated that with adequate counselling, TB patients with HIV 
co-infection may have improved treatment adherence (Amuha, Kutyabami, Kitutu, Odoi-
adome, & Kalyango, 2009). It is therefore important that MDR-TB programs include 
counselling sessions for patients with HIV co-morbidity to address issues such as pill 
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burden, side effects of the medications and the stress associated with seeking care for 
both diseases, among others. 
These findings may be applied to inform the health education programs to address 
the factors that will impact negatively on treatment adherence. Also, based on the finding 
that age is a predictor of treatment outcomes, it is important to develop campaigns and 
health education programs that are age-sensitive. These health education programs should 
target the characteristics of the older population that may act as barriers to treatment 
compliance. Similarly, the health education programs will be informed by the core 
constructs of HBM which include self-efficacy to comply to MDR-TB treatment, 
personal perception of risk, perceived severity of MDR-TB, perceived threat of having 
unsuccessful treatment outcomes when treatment adherence is not achieved and on the 
other side, the perception of health benefits if treatment adherence is achieved. I will 
apply HBM to emphasize the negative consequences of poor treatment adherence and to 
develop messages that are targeted toward addressing the probable factors that may likely 
lead to poor treatment compliance. According to the findings of this study, these include 
being single, being male, older age, enrolled on community model of care and having a 
positive HIV status.  
The behavioral patterns that are related to poor treatment adherence may also be 
easy to decipher as well as the barriers to treatment adherence based on the characteristics 
of the patients. Family support from a close partner may be responsible for the better 
adherence seen in the married group relative to the single patients, however, support 
systems can be tailored to address this social need. The MDR-TB program currently 
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employs the use of treatment supporters and this can be emphasized particularly for the 
single patients. Also, this may inform the need to prioritize family members as treatment 
supporters and to design special health education programs for them such that they are 
also aware of the benefits of treatment adherence and the negative consequences of not 
adhering to the MDR-TB treatment regimen.  
A study identified key barriers to treatment adherence among TB patients in 
general across several settings including Nigeria, they include smoking, male gender, 
feeling better, long distance to health facility, social stigma, lack of social support, 
alcohol use, being on ARV, lack of knowledge among others (Tola, Shojaeizadeh, & 
Garmaroudi, 2015). Based on the findings of this study, it is critical that potential barriers 
to treatment adherence are overcome by designing interventions that are targeted at the 
patients that are more likely not to adhere to treatment. The focus of the interventions 
should be to heighten their perceived personal risk of unsuccessful treatment outcome by 
describing the negative consequences of non-compliance and emphasizing the benefit of 
compliance which is having a successful treatment outcome. The threat-based approach 
can be used during counselling sessions by sharing the stories of patients who died due to 
poor treatment compliance. Considering that a key construct of the HBM is the 
individual’s self-efficacy which in this case describes the MDR-TB patient’s innate 
ability to comply to treatment, emphasis should be placed on building the patient’s 
capacity to address both individual and environmental factors that may deter treatment 
adherence. Hence, with due consideration to the model of care a patient is enrolled in, 
adequate health education should be provided to ensure treatment adherence. Similarly, 
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such health education packages should be tailored to address individual patient’s needs 
and risk factors for poor treatment compliance.  
Limitations of the Study 
For this study, I employed a retrospective cohort design; hence, it was difficult to 
collect information on potential confounding factors that may have led to the associations 
or lack thereof, that I observed in the results of the study. Similarly, issues with data 
completeness and accuracy are usually not easily addressed when using a retrospective 
cohort design; hence, for this study, I excluded incomplete records from the analysis. 
Also, it was difficult to differentiate patients who died as a result of MDR-TB from those 
who died from other causes. In addition, I used a quantitative approach without the 
qualitative method, meaning I was not able to explore the experiences and perspectives of 
the patients about the treatment and how this may have impacted the observed treatment 
outcomes. In my investigation, I focused on the relationship between model of care and 
treatment outcomes, limiting models of care to just community-based and ambulatory 
models, which may not have accounted for variants that may exist such as some patients 
that may have to be admitted in hospitals in the course of their treatment due to adverse 
drug reactions or other causes of illness while being classified as patients managed in the 
community. 
Existence of co-morbidities only included HIV. I did not investigate the effect of 
having diabetes as a co-morbidity because it was difficult to retrieve the diabetes status of 
the patients as diabetes tests and results are not included in the routine data collected on 
the National TB program. I also chose not to consider all other health conditions such as 
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hypertension, heart diseases, malaria, typhoid and other common health conditions in the 
country due to this gap in routine data collection on the program. While the scope of the 
study did not cover these illnesses, they may, nonetheless, be associated with the 
observed treatment outcomes. I did not investigate health workers’ attitude and the kind 
of social support provided to the patients in this study in spite of the fact that these factors 
may have effect on the observed treatment outcomes. I included only patients managed in 
Nigeria between 2013 and 2014 in this study. This is because the community-based 
model of care became fully operational in Nigeria in 2013 and the cohort analysis of 
patients beyond 2014 was not readily available as at the time this study was conducted.   
Recommendations 
The findings of this survey provided insight into how model of care, demographic 
factors such age and gender, marital status and HIV comorbidity affect treatment 
outcomes among MDR-TB patients. Based on the results of the study, community model 
of MDR-TB treatment compared favorably with the hospital-based approach; hence, I 
recommend a rapid scale up of the community model in states with high burden of TB to 
meet the high demand for MDR-TB. Older and other high risk patients may be 
considered strictly for the hospital-based model of care.  
The findings of this study were based on the analysis of secondary data; I was 
unable to provide the reasons behind the associations or lack thereof that I observed 
between the variables I investigated in relation to MDR-TB treatment outcomes. Against 
this backdrop, qualitative studies using in-depth interviews to explore patients’ 
perspectives on their treatment experience for both the community and the hospital-based 
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model of care are essential for many reasons. Key among these reasons is the need to 
better understand the contextual factors relating to health worker’s attitude, direct and 
indirect costs associated with MDR-TB treatment and how they impact on the patients’ 
lives, and more importantly how patients are affected by the adverse events associated 
with MDR-TB treatment and how they navigate the difficult period of undergoing MDR-
TB treatment. Also, it is critical to understand the reasons behind the patterns of 
treatment default observed in this study and why the behavior may be modified by age, 
gender, marital status, model of care and presence of HIV comorbidity. A deeper 
understanding of the reasons for non-adherence to treatment will provide the insights 
needed to design effective programmatic interventions that can address the barriers to 
treatment compliance. Overall, more qualitative evidence is needed to refine existing 
policies and guidelines for managing MDR-TB in Nigeria toward a more patient-centered 
approach to treatment. 
This study should provide the baseline for further explorative investigation to understand 
the contextual factors that affect MDR-TB treatment outcomes as well as the pathway 
between treatment enrollment and completion and how they interface with individual, 
organizational and societal factors that modify behaviors during the treatment period. 
Furthermore, in line with the findings of this study, it is critical to further investigate the 
association between age and treatment outcomes as well as how the presence of other 
comorbidities such as diabetes, hypertension and other morbidities associated with old 
age may have confounded the association between age and treatment outcomes.  
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Implication for Professional Practice and Social Change 
The findings of this study show that management of MDR-TB patients in 
communities results in similar treatment outcomes as the hospital-based approach. This 
study provides the empirical evidence needed to support the rapid expansion of the 
community model of care for MDR-TB management in Nigeria 
Professional Practice 
The findings of this study show the need for continuous review of programmatic 
responses to disease control especially when managing difficult diseases such as MDR-
TB. It is important that policies are backed by local empirical evidence that captures the 
country-level experience and context. This will support the implementation of effective 
health interventions that are tailored toward addressing factors that may affect the quality 
of treatment available to MDR-TB patients. I based this study on the analysis of 
secondary data collected as part of the routine data collected through the M&E system of 
the National TB program. In line with this, it is essential that programmatic data that are 
collected routinely are reviewed quantitatively to identify key factors that may be 
associated with quality of treatment and patients’ outcome. This approach provides a 
cost-effective way to synthesize the evidence needed to improve the way health 
programs, which in this context is MDR-TB management, are implemented. 
Similarly, the findings of this study showed that patients managed in the hospital 
have similar treatment outcomes as those managed in the community. This is an 
indication that the National TB program has effectively deployed the newer model of 
care which is the community-based approach to manage MDR-TB patients. There are 
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many programmatic challenges that abound with managing MDR-TB patients in the 
community. They include adverse drug events and reactions to the toxic second line 
drugs for managing MDR-TB, ensuring optimal infection control practices when patients 
are managed in their homes, among others. Considering all these challenges, the 
similarity in treatment success rates for the two models of care is a good development 
and provides the empirical evidence needed to support the rapid scale-up of community 
management of MDR-TB patients. It is, however, critical, when considering the patient-
centered approach to TB management, to ensure that the selection of the model of care to 
be employed per patient is given careful consideration with regards to living 
circumstances, age, other co-morbidities, among other factors. 
Positive Social Change 
The findings of this study showed that while treatment outcomes between the two 
models of care may be similar, old age is a predisposing factor for poor treatment 
outcome. In line with the international standard for TB care which emphasizes a patient-
centered approach to TB management, it is critical that this factor is given full 
consideration when designing and implementing MDR-TB care. MDR-TB programs in 
Nigeria should therefore be robust enough to accommodate the peculiar issues associated 
with old age that may predispose to poor treatments. Similarly, this study can form the 
basis for developing a special treatment package for patients aged above 40 years. This 
package may include health education, social support from family and non-family 
members as well as counseling sessions with health workers to ensure treatment 
adherence and early identification of adverse drug events. Other implications for social 
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change may be the need to review the existing guidelines and policies for managing 
MDR-TB patients in line with the findings of this study. Such changes may include the 
need for age-specific management approaches. Similarly, rapid and urgent scale up of 
community model of care in all the states in the country is recommended to address the 
gap in MDR-TB case detection and enrollment for care. By ensuring that all MDR-TB 
patients have access to immediate care, the country stands a better chance to curb the 
spread of primary MDR-TB infection and to reduce the high morbidity and mortality 
rates associated with the disease.  
The findings of this study may also be useful toward developing effective health 
education programs that are tailored toward addressing the probable factors that may 
predispose to non-adherence at the individual and societal levels. 
Conclusion 
The findings of this study suggest that the outcomes of treatment for patients 
managed in the community are fairly similar to those managed in a hospital. Also, age 
was shown to be significantly associated with treatment outcomes with older patients 
having more likelihood of a poor treatment outcome than their younger counterparts. 
These key findings provide the empirical evidence needed to rapidly and urgently expand 
the community-based model of MDR-TB care in Nigeria. Considering that the health 
systems of the country are already overwhelmed with other infectious diseases such as 
HIV/AIDs and other non-communicable diseases, the expansion of community model of 
care may reduce the burden MDR-TB places on the health facilities. Also, community 
model of care has been found to be a cost-effective approach to managing MDR-TB care; 
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hence, deploying more patients for community management after a careful review of 
their health conditions and social support systems may free up costs that can be used to 
treat more MDR-TB patients and, possibly, address other health issues. Summarily, all 
the findings of this study should inform policy changes that will ultimately improve the 
quality of care provided to MDR-TB patients in Nigeria. 
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